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ABSTRACT: A one-pot multibond-forming process involving
a thermally mediated Overman rearrangement and a ring
closing metathesis reaction of allylic trichloroacetimidates
bearing a 2-allyloxyaryl group has been developed for the
synthesis of 5-amino-substituted 2,5-dihydro-1-benzoxepines.
Chemoselective reduction and functionalization of these
compounds allowed access to a range of pharmacologically
active 5-amino-2,3,4,5-tetrahydro-1-benzoxepine scaﬀolds.
■ INTRODUCTION
Dihydrobenzo[b]oxepines are an important class of seven-
membered heterocyclic compound found as a key constituent
in a variety of natural products and biologically active
substances.1−3 In particular, 2,5-dihydro-1-benzoxepines such
as radulanin A (1)4 and heliannuol B5 were isolated from
liverwort and sunﬂowers, respectively, while 2,3-dihydro-1-
benzoxepines including pterulone (2) have been recovered
from various fungi and shown to possess antibiotic activity
(Figure 1).1,3
As a result of their biological signiﬁcance and interesting
structures, various methods for the preparation of these
compounds have been reported. 2,3-Dihydro-1-benzoxepines
have been synthesized by metal catalyzed formation of the
oxepine ring using suitably derived phenol ethers and alkynes6,7
and also via a Wittig homologation of 2-(chloromethyl)-2H-
chromen-2-ol derivatives.8 A variety of methods have also been
reported for the preparation of 2,5-dihydro-1-benzoxepines.9−13
These include a general approach involving the Claisen
rearrangement of allyl phenyl ethers followed by O-allylation
and a ring closing metathesis (RCM) reaction (Scheme 1a).11
This particular strategy has been utilized for the total synthesis
of a number of 2,5-dihydro-1-benzoxepine-containing natural
products.2,12,13
Building on the general strategy of using sigmatropic
rearrangements in combination with RCM reactions for the
synthesis of medium-sized heterocycles (Scheme 1a) and our
previous work on the development of one-pot multistep
reactions,14−16 we were interested in developing an approach
for the synthesis of 5-amino-2,5-dihydro-1-benzoxepines
(Scheme 1b). Previous one-pot methods developed by our
group for the preparation of seven-membered ring systems have
encountered issues during the metathesis step, such as the
formation of dimeric products,14a and the requirement of
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Figure 1. Structures of dihydro-1-benzoxepine natural products (1 and
2) and biologically active amino-substituted 2,3,4,5-tetrahydro-1-
benzoxepines (3 and 4).
Scheme 1. 3,3-Sigmatropic Rearrangement and RCM Routes
to 2,5-Dihydro-1-benzoxepines
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pubs.acs.org/joc
© 2015 American Chemical Society 4683 DOI: 10.1021/acs.joc.5b00583
J. Org. Chem. 2015, 80, 4683−4696
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
forcing conditions to form the seven-membered ring in good
yields.15a In this current study, we wished to investigate
whether more rigid alkene derived allylic alcohols bearing an
aromatic ring would prove to be more suitable substrates for
such a process, yielding a library of 5-amino-2,5-dihydro-1-
benzoxepines. Subsequent oxidation or chemoselective reduc-
tion of the alkene moiety of these targets would then allow
access to functionalized 5-amino-2,3,4,5-tetrahydro-1-benzox-
epines that are present in a wide range of pharmacologically
active compounds (e.g., 3 and 4, Figure 1).17−20 We now report
an eﬃcient synthesis of 5-amino-2,5-dihydrobenzoxepines from
commercially available salicylaldehydes using a one-pot multi-
bond-forming process for introduction of the amine function-
ality and consecutive formation of the oxepine ring. As well as
demonstrating the general scope of this strategy, we also
explore the synthetic utility of 5-amino-2,5-dihydro-1-benzox-
epines for the preparation of 2,3,4,5-tetrahydro-1-benzoxepine
targets.
■ RESULTS AND DISCUSSION
The study began with the development of a general approach
for the synthesis of (E)-(2-allyloxy)cinnamyl alcohols from
readily available salicylaldehydes (Scheme 2). O-Allylation of
salicylaldehydes 5a−l under standard conditions gave 2-
allyloxybenzaldehydes 6a−l, and these were subjected to a
Horner−Wadsworth−Emmons (HWE) reaction with triethyl
phosphonoacetate (TEPA) under mild Masamune−Roush
conditions.21 Reduction of the resulting (E)-α,β-unsaturated
esters 7a−l with DIBAL-H completed the three-step synthesis
of (E)-(2-allyloxy)cinnamyl alcohols 8a−l in high overall yields.
The one-pot multibond-forming process was then optimized
for the synthesis of 5-amino-substituted 2,5-dihydro-1-benzox-
epine 11a (Table 1). (E)-(2-Allyloxy)cinnamyl alcohol 8a was
converted to the corresponding allylic trichloroacetimidate
using trichloroacetonitrile and a catalytic amount of DBU and
then subjected to an Overman rearrangement under thermal
conditions (entry 1).22 Grubbs ﬁrst-generation catalyst was
initially investigated for the RCM step and required a catalyst
loading of 30 mol % and a reaction time of 120 h for complete
conversion.23 This gave 2,5-dihydro-1-benzoxepine 11a in 15%
yield over the three steps. On analysis of the process, it was
found that the typical workup procedure of allylic trichlor-
oacetimidate formation by ﬁltration of the reaction mixture
through a plug of silica gel, resulted in substantial
decomposition of 9a. This is likely promoted by the presence
of the electron-rich ortho-ether unit and the acidic nature of the
silica gel. In subsequent studies of the one-pot process, this
issue was overcome by simply performing the ﬁltration using
neutral alumina. Using this modiﬁcation, the one-pot process
was repeated, and 11a was isolated in a signiﬁcantly improved
63% overall yield (entry 2). The use of a palladium(II)-
catalyzed Overman rearrangement was next investigated, and
while this transformation was conducted under mild conditions,
2,5-dihydro-1-benzoxepine 11a was isolated in only 26% yield
(entry 3). The low yield is likely due to a number of factors
such as a competing 1,3-rearrangement as well as coordination
of the palladium(II)-catalyst with the allylic ether moiety
preventing eﬀective activation and rearrangement of the allylic
trichloroacetimidate.15a Finally, the use of a one-pot process
involving a thermally mediated Overman rearrangement in
combination with Grubbs second-generation catalyst was
examined, and this resulted in a substantial improvement of
reaction conditions for the RCM step (entry 4).24 After 20 h,
complete conversion could be achieved using a 5 mol % catalyst
loading, resulting in the isolation of 2,5-dihydro-1-benzoxepine
11a in 68% yield from allylic alcohol 8a.
Using these optimized conditions, the scope of the one-pot
process for the synthesis of a small library of 5-amino-
substituted 2,5-dihydro-1-benzoxepines was explored (Scheme
3). Overall, this approach was found to be general for a range of
substituents and substitution patterns. For example, compar-
ison of the same substituent at ortho-, meta-, or para-positions
showed no signiﬁcant diﬀerence in reactivity, giving the ﬁnal
products in comparable yields (11b/c/d and 11g/i). Substrates
bearing strongly electron-deﬁcient substituents did require
Scheme 2. Synthesis of Allylic Alcohols 8a−l
Table 1. Optimization of the One-Pot Process
entry Overman rearrangement RCM reaction
yield
(%)
1a K2CO3, 140 °C Grubbs I (30 mol %),
120 h
15
2b K2CO3, 140 °C Grubbs I (30 mol %),
120 h
63
3b Pd(MeCN)2Cl2 (10 mol %),
rt
Grubbs I (30 mol %),
120 h
26
4b K2CO3, 140 °C Grubbs II (5 mol %), 20 h 68
aAllylic trichloroacetimidate 9a was isolated by ﬁltration of the
reaction mixture through a plug of silica gel. bAllylic trichloroaceti-
midate 9a was isolated by ﬁltration of the reaction mixture through a
plug of neutral alumina.
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.5b00583
J. Org. Chem. 2015, 80, 4683−4696
4684
extended reaction times for the Overman rearrangement,
however, these one-pot processes still produced the corre-
sponding 2,5-dihydro-1-benzoxepines in high yields (11f−j).
Only products 11k and 11l were isolated in modest yields, and
this is likely due to the increased steric bulk associated with the
aryl substituents.
Derivatives of 5-amino-substituted 2,3,4,5-tetrahydro-1-ben-
zoxepines bearing aryl groups at the 8-postion (e.g., 20, Scheme
4) have been shown to be potent inhibitors of acyl-CoA
cholesterol O-acyl transferase (ACAT), the enzyme responsible
for intracellular esteriﬁcation of cholesterol.19 Due to the
signiﬁcant biological activity of these compounds, the scope of
our one-pot synthesis of 2,5-dihydro-1-benzoxepines was
extended to investigate the rapid assembly of this type of
oxepine skeleton (Scheme 4). Initially, Suzuki−Miyaura
coupling of 4-ﬂuorophenylboronic acid (12) and methyl 2-
hydroxy-4-iodobenzoate (13) gave biaryl compound 14 in
quantitative yield. Reduction of the ester with lithium
aluminum hydride and selective allylation of the phenol gave
benzyl alcohol 15. This was then subjected to a one-pot Swern
oxidation and HWE reaction, which gave (E)-α,β-unsaturated
ester 16 as the sole product in 84% yield over the two steps.
DIBAL-H reduction of the ester then completed the six-step
synthesis of allylic alcohol 17. Formation of the corresponding
allylic trichloroacetimidate and application of the one-pot
Overman rearrangement and RCM process using the optimized
conditions proceeded smoothly, giving 2,5-dihydro-1-benzox-
epine 18 in 98% yield. The synthesis of 18 in 61% overall yield
from commercially available benzoate 13 demonstrates the
robust nature of the one-pot strategy for the synthesis of
pharmacologically important 5-amino-substituted 2,5-dihydro-
1-benzoxepine building blocks.
Having explored the scope of the one-pot process, the next
stage of this research program investigated the synthetic utility
of these compounds for the preparation of biologically active
scaﬀolds. As 5-amino-substituted 2,3,4,5-tetrahydro-1-benzox-
epines have wide ranging pharmacological activities,17−20
chemoselective methods for their synthesis from 2,5-dihydro-
1-benzoxepines were developed. A method that would allow
preparation of the ACAT inhibitor core by reduction of the
alkene moiety of 18 while retaining the trichloroacetamide as a
protecting group was initially examined. Standard hydro-
genation conditions (10% Pd/C in an atmosphere of H2)
gave 19 in 59% yield. However, several byproducts formed via
reduction of the trichloromethyl group were also isolated.
Instead, a more selective reaction for the preparation of 19 was
achieved using diimide, which was generated in situ from p-
toluenesulfonyl hydrazide and potassium acetate (Scheme 4).25
This produced 2,3,4,5-tetrahydro-1-benzoxepine 19 more
cleanly in 81% yield.
A synthesis of 8-chloro-5-guanidino-2,3,4,5-tetrahydro-1-
benzoxepine (4), a known hypotensive agent was developed
from 2,5-dihydro-1-benzoxepine 11i (Scheme 5).20 In this case,
introduction of the guanidine moiety required removal of the
trichloroacetamide, and so no eﬀort was made to maintain this
group during reduction of the alkene. Hydrogenation of 11i
under standard conditions resulted in reduction of both the
alkene and the trichloromethyl group giving 21 as the sole
product in 94% yield. Acid hydrolysis of the dichloromethy-
lacetamide group required forcing conditions but did yield the
corresponding amine cleanly. This was coupled with
commercially available N,N′-bis(tert-butoxycarbonyl)-1H-pyra-
zole-1-carboxamidine (22) in the presence of Hünig’s base, and
this gave guanidine 23 in 75% yield over the two steps.26,27
Finally, removal of the Boc-protecting groups using TFA
completed the 10-step synthesis of hypotensive agent 4 in 40%
overall yield from commercially available 4-chloro-2-hydrox-
ybenzaldehyde (5i).
A number of 5-amino-substituted 2,3,4,5-tetrahydro-1-
benzoxepines bearing hydroxyl groups have displayed pharma-
cological activity (e.g., 3, Figure 1).17a,c,18 For this reason and
the considerable interest in the medicinal chemistry applica-
tions of the vicinal amino diol motif,28 the ﬁnal stage of this
research program explored the directed oxidation of 5-amino-
substituted 2,5-dihydro-1-benzoxepines for the preparation of
syn- and anti-3,4-diol analogues. While directed dihydroxyla-
tion29 and epoxidation30 of a number of cyclic allylic
trichloroacetamide systems has been described, we were
interested in the outcome of these reactions using 5-amino-
substituted 2,5-dihydro-1-benzoxepines as novel substrates.
Reaction of 6-methoxy-2,5-dihydro-1-benzoxepine 11b with
osmium tetroxide and TMEDA under Donohoe conditions
gave the corresponding (3R*,4S*,5S*)-diol 24 in 74% yield
(Scheme 6).29 Inspection of the 1H NMR spectra of the crude
material from this reaction showed only one diastereomer, with
Scheme 3. Synthesis of 5-Amino-Substituted 2,5-Dihydro-1-
benzoxepines 11a−l
aThe Overman rearrangement required an extended reaction time (24
h, 11i and 11j; 48 h, 11h and 11k; 60 h, 11f and 11g). b7.5 mol % of
Grubbs second-generation catalyst was used for the RCM step.
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NOE experiments clearly demonstrated the syn-relationship of
the vicinal amino diol motif. This result suggests that the
trichloroacetamide unit of the oxepine ring systems is able to
facilitate a highly eﬀective, directed dihydroxylation with the
complex formed from osmium tetroxide and TMEDA.
Directed epoxidation of 7-chloro-2,5-dihydro-1-benzoxepine
11g and subsequent acid mediated ring opening for the
preparation of the anti-3,4-diol was next investigated and found
to be less selective. Treatment of 11g with m-CPBA gave the
corresponding epoxide in a 12:1 diastereoselectivity (Scheme
6). Again NOE experiments conﬁrmed the all syn-diastereomer
25 as the major product, formed via a substrate-directed
process that is in agreement with Henbest’s rule.30,31 Without
puriﬁcation, regioselective hydrolysis of epoxide 25 under acidic
conditions gave after puriﬁcation, the (3S*,4S*,5S*)-diol 26 in
good yield over the two steps. The diﬀerence in selectivity
Scheme 4. Synthesis of 5-Amino-Substituted 2,3,4,5-Tetrahydro-1-benzoxepine 19
Scheme 5. Synthesis of 8-Chloro-5-guanidino-2,3,4,5-
tetrahydro-1-benzoxepine (4)
Scheme 6. Dihydroxylation of 5-Amino-Substituted 2,5-
Dihydro-1-benzoxepines
aRatio of major (3R*,4S*,5S*)-25 and minor (3S*,4R*,5S*) epoxide
diastereomers.
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.5b00583
J. Org. Chem. 2015, 80, 4683−4696
4686
between the dihydroxylation and epoxidation processes is likely
a direct reﬂection of the ability of the reagents of these
reactions to undergo hydrogen-bonding substrate-directed
reactions with the allylic trichloroacetamide oxepine unit.
Seven-membered heterocyclic ring systems such as azepanes
bearing an allylic trichloroacetamide moiety have demonstrated
similar selectivity and overall yields for these oxidation
processes.15b
■ CONCLUSIONS
In summary, a general approach has been developed for the
preparation of 2,5-dihydro-1-benzoxepines. A three-step syn-
thesis of 2-allyloxycinnamyl alcohol derivatives from readily
available 2-hydroxybenzaldehydes was followed by imidate
formation and a one-pot Overman rearrangement and RCM
process, allowing access to a diverse library of 5-amino-2,5-
dihydro-1-benzoxepines in high overall yields. Further
functionalization of these privileged structures was explored.
Chemoselective reduction or substrate-directed oxidation of the
alkene moiety generated a series of 5-amino-2,3,4,5-tetrahydro-
1-benzoxepines, compounds which display a wide range of
pharmacological activities. Work is currently underway to
extend the application of this one-pot multibond-forming
reaction process for the preparation of biologically relevant
polycyclic classes of compounds.
■ EXPERIMENTAL SECTION
All reagents and starting materials were obtained from commercial
sources and used as received. All dry solvents were puriﬁed using a
solvent puriﬁcation system. All reactions were performed under an
atmosphere of argon unless otherwise mentioned. Brine refers to a
saturated solution of sodium chloride. Flash column chromatography
was performed using silica gel 60 (35−70 μm). Aluminum-backed
plates precoated with silica gel 60F254 were used for thin-layer
chromatography and were visualized with a UV lamp or by staining
with potassium permanganate. 1H NMR spectra were recorded on a
NMR spectrometer at either 400 or 500 MHz, and data are reported as
follows: chemical shift in ppm relative to tetramethylsilane as the
internal standard, multiplicity (s = singlet, d = doublet, t = triplet, q =
quartet, m = multiplet or overlap of nonequivalent resonances,
integration). 13C NMR spectra were recorded on a NMR spectrometer
at either 101 or 126 MHz, and data are reported as follows: chemical
shift in ppm relative to tetramethylsilane or the solvent as internal
standard (CDCl3, δ 77.0 ppm or CD3OD, δ 44.0 ppm), multiplicity
with respect to hydrogen (deduced from DEPT experiments, C, CH,
CH2 or CH3). Infrared spectra were recorded on a FTIR
spectrometer; wavenumbers are indicated in cm−1. Mass spectra
were recorded using electron impact, chemical ionization, or
electrospray techniques. HRMS spectra were recorded using a dual-
focusing magnetic analyzer mass spectrometer. Melting points are
uncorrected.
2-Allyloxybenzaldehyde (6a).32 Allyl bromide (0.98 mL, 1.3
mmol) was added to a stirred solution of 2-hydroxybenzaldehyde (5a)
(0.10 mL, 0.94 mmol) and potassium carbonate (0.26 g, 1.9 mmol) in
N,N′-dimethylformamide (10 mL) and warmed to 70 °C for 2 h. The
reaction was cooled to room temperature, diluted with 5% aqueous
lithium chloride solution (20 mL), and extracted with diethyl ether (20
mL). The organic layer was washed with 5% aqueous lithium chloride
solution (3 × 10 mL), brine (10 mL), dried (MgSO4), ﬁltered, and
concentrated in vacuo. Puriﬁcation by column chromatography
(elution with 20% diethyl ether in petroleum ether) gave 2-
allyloxybenzaldehyde (6a) (0.15 g, 99%) as a colorless oil.
Spectroscopic data were in accordance with literature values.32 1H
NMR (400 MHz, CDCl3) δ 4.66 (dt, J = 5.1, 1.5 Hz, 2H), 5.34 (dq, J
= 10.5, 1.5 Hz, 1H), 5.45 (dq, J = 17.3, 1.5 Hz, 1H), 6.08 (ddt, J =
17.3, 10.5, 5.1 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 7.03 (br t, J = 7.5 Hz,
1H), 7.53 (ddd, J = 8.4, 7.5, 1.9 Hz, 1H), 7.84 (dd, J = 7.5, 1.9 Hz,
1H), 10.54 (d, J = 0.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 69.4
(CH2), 113.0 (CH), 118.2 (CH2), 121.0 (CH), 125.3 (C), 128.6
(CH), 132.6 (CH), 135.9 (CH), 161.1 (C), 189.9 (CH); MS (CI) m/
z 163 (MH+, 100), 135 (34), 121 (8), 85 (12), 79 (11).
2-Allyloxy-6-methoxybenzaldehyde (6b).32 The reaction was
carried out as described for the synthesis of 2-allyloxybenzaldehyde
(6a) using 2-hydroxy-6-methoxybenzaldehyde (5b) (0.500 g, 3.29
mmol). This gave 2-allyloxy-6-methoxybenzaldehyde (6b) (0.559 g,
88%) as a yellow oil. Spectroscopic data were in accordance with
literature values.32 1H NMR (400 MHz, CDCl3) δ 3.90 (s, 3H), 4.63
(dt, J = 5.0, 1.4 Hz, 2H), 5.31 (dq, J = 10.4, 1.4 Hz, 1H), 5.48 (dq, J =
17.3, 1.4 Hz, 1H), 6.05 (ddt, J = 17.3, 10.4, 5.0 Hz, 1H), 6.56 (d, J =
8.5 Hz, 1H), 6.58 (d, J = 8.5 Hz, 1H), 7.42 (t, J = 8.5 Hz, 1H), 10.56
(s, 1H); 13C NMR (101 MHz, CDCl3) δ 56.2 (CH3), 69.7 (CH2),
104.2 (CH), 105.3 (CH), 115.0 (C), 117.9 (CH2), 132.6 (CH), 135.8
(CH), 161.6 (C), 162.0 (C), 189.4 (CH); MS (ESI) m/z 215 (MNa+,
100), 187 (10), 174 (20), 137 (5).
2-Allyloxy-5-methoxybenzaldehyde (6c).33 The reaction was
carried out as described for the synthesis of 2-allyloxybenzaldehyde
(6a) using 2-hydroxy-5-methoxybenzaldehyde (5c) (0.41 mL, 3.30
mmol). This gave 2-allyloxy-5-methoxybenzaldehyde (6c) (0.60 g,
96%) as a yellow oil. Spectroscopic data were in accordance with
literature values.33 1H NMR (400 MHz, CDCl3) δ 3.80 (s, 3H), 4.61
(d, J = 5.2 Hz, 2H), 5.31 (dd, J = 10.6, 1.4 Hz, 1H), 5.43 (dd, J = 17.1,
1.4 Hz, 1H), 6.06 (ddt, J = 17.1, 10.6, 5.2 Hz, 1H), 6.93 (d, J = 9.1 Hz,
1H), 7.11 (dd, J = 9.1, 3.3 Hz, 1H), 7.33 (d, J = 3.3 Hz, 1H), 10.49 (s,
1H); 13C NMR (101 MHz, CDCl3) δ 56.0 (CH3), 70.2 (CH2), 110.4
(CH), 115.1 (CH), 118.1 (CH2), 123.6 (CH), 125.6 (C), 132.8 (CH),
154.0 (C), 155.9 (C), 189.6 (CH); MS (ESI) m/z 215 (MNa+, 40),
206 (30), 174 (100).
2-Allyloxy-4-methoxybenzaldehyde (6d).33 The reaction was
carried out as described for the synthesis of 2-allyloxybenzaldehyde
(6a) using 2-hydroxy-4-methoxybenzaldehyde (5d) (0.500 g, 3.29
mmol). This gave 2-allyloxy-4-methoxybenzaldehyde (6d) (0.583 g,
92%) as a colorless oil. Spectroscopic data were in accordance with
literature values.33 1H NMR (500 MHz, CDCl3) δ 3.85 (s, 3H), 4.62
(dt, J = 5.1, 1.5 Hz, 2H), 5.33 (dq, J = 10.5, 1.5 Hz, 1H), 5.45 (dq, J =
17.3, 1.5 Hz, 1H), 6.06 (ddt, J = 17.3, 10.5, 5.1 Hz, 1H), 6.43 (d, J =
2.2 Hz, 1H), 6.54 (ddd, J = 8.7, 2.2, 0.6 Hz, 1H), 7.81 (d, J = 8.7 Hz,
1H), 10.35 (d, J = 0.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 55.8
(CH3), 69.3 (CH2), 99.2 (CH), 106.2 (CH), 118.2 (CH2), 119.4 (C),
130.6 (CH), 132.4 (CH), 162.8 (C), 166.2 (C), 188.4 (CH); MS
(ESI) m/z 215 (MNa+, 100), 187 (7), 174 (7), 159 (3).
2-Allyloxy-5-methylbenzaldehyde (6e).33 The reaction was
carried out as described for the synthesis of 2-allyloxybenzaldehyde
(6a) using 2-hydroxy-5-methylbenzaldehyde (5e) (0.136 g, 1.00
mmol). This gave 2-allyloxy-5-methylbenzaldehyde (6e) (0.173 g,
98%) as a colorless oil. Spectroscopic data were in accordance with
literature values.33 1H NMR (500 MHz, CDCl3) δ 2.31 (s, 3H), 4.63
(dt, J = 5.2, 1.6 Hz, 2H), 5.32 (dq, J = 10.6, 1.6 Hz, 1H), 5.44 (dq, J =
17.3, 1.6 Hz, 1H), 6.07 (ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 6.88 (d, J =
8.5 Hz, 1H), 7.33 (ddd, J = 8.5, 2.3, 0.6 Hz, 1H), 7.64 (d, J = 2.3 Hz,
1H), 10.51 (s, 1H); 13C NMR (126 MHz, CDCl3) δ 20.3 (CH3), 69.3
(CH2), 113.0 (CH), 117.9 (CH2), 124.9 (C), 128.5 (CH), 130.3 (C),
132.6 (CH), 136.5 (CH), 159.1 (C), 189.9 (CH); MS (ESI) m/z 199
(MNa+, 100), 190 (3), 185 (4), 171 (5), 158 (16), 136 (2).
2-Allyloxy-5-nitrobenzaldehyde (6f).34 The reaction was
carried out as described for the synthesis of 2-allyloxybenzaldehyde
(6a) using 2-hydroxy-5-nitrobenzaldehyde (5f) (0.050 g, 0.32 mmol).
This gave 2-allyloxy-5-nitrobenzaldehyde (6f) (0.061 g, 98%) as a
white solid. Mp 62−64 °C (lit.34 63−65 °C); 1H NMR (400 MHz,
CDCl3) δ 4.80 (dt, J = 5.3, 1.4 Hz, 2H), 5.41 (ddt, J = 10.7, 2.5, 1.4
Hz, 1H), 5.48 (ddt, J = 17.3, 2.5, 1.4 Hz, 1H), 6.08 (ddt, J = 17.3, 10.7,
5.3 Hz, 1H), 7.11 (d, J = 9.2 Hz, 1H), 8.39 (dd, J = 9.2, 2.9 Hz, 1H),
8.67 (d, J = 2.9 Hz, 1H), 10.48 (s, 1H); 13C NMR (101 MHz, CDCl3)
δ 70.3 (CH2), 113.5 (CH), 119.6 (CH2), 124.7 (CH), 124.8 (C) 130.6
(CH), 131.1 (CH), 141.7 (C), 164.7 (C), 187.6 (CH); MS (CI) m/z
208 (MH+, 100), 178 (45), 168 (13), 138 (16), 113 (21), 97 (18), 81
(32), 69 (33).
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2-Allyloxy-5-chlorobenzaldehyde (6g).35 The reaction was
carried out as described for the synthesis of 2-allyloxybenzaldehyde
(6a) using 2-hydroxy-5-chlorobenzaldehyde (5g) (0.500 g, 3.18
mmol). This gave 2-allyloxy-5-chlorobenzaldehyde (6g) (0.61 g,
96%) as a white solid. Mp 99−101 °C (lit.35 101−102 °C); 1H NMR
(400 MHz, CDCl3) δ 4.65 (dt, J = 5.2, 1.5 Hz, 2H), 5.35 (dq, J = 10.6,
1.5 Hz, 1H), 5.44 (dq, J = 17.3, 1.5 Hz, 1H), 6.06 (ddt, J = 17.3, 10.6,
5.2 Hz, 1H), 6.93 (d, J = 8.9 Hz, 1H), 7.47 (dd, J = 8.9, 2.8 Hz, 1H),
7.79 (d, J = 2.8 Hz, 1H), 10.46 (s, 1H); 13C NMR (101 MHz, CDCl3)
δ 69.8 (CH2), 114.7 (CH), 118.7 (CH2), 126.1 (C), 126.7 (C), 128.1
(CH), 132.1 (CH), 135.4 (CH), 159.5 (C), 188.5 (CH); MS (CI) m/
z 197 (MH+, 100), 169 (13), 157 (4), 81 (11), 69 (18).
2-Allyloxy-5-bromobenzaldehyde (6h).35 The reaction was
carried out as described for the synthesis of 2-allyloxybenzaldehyde
(6a) using 2-hydroxy-5-bromobenzaldehyde (5h) (0.500 g, 2.49
mmol). This gave 2-allyloxy-5-bromobenzaldehyde (6h) (0.591 g,
99%) as a white solid. Mp 35−37 °C; Spectroscopic data were in
accordance with literature values.35 1H NMR (400 MHz, CDCl3) δ
4.65 (dt, J = 5.2, 1.5 Hz, 2H), 5.35 (dq, J = 10.6, 1.5 Hz, 1H), 5.44 (dq,
J = 17.3, 1.5 Hz, 1H), 6.05 (ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 6.88 (d, J
= 8.9 Hz, 1H), 7.60 (dd, J = 8.9, 2.6 Hz, 1H), 7.93 (d, J = 2.6 Hz, 1H),
10.44 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 69.7 (CH2), 113.8 (C),
115.1 (CH), 118.7 (CH2), 126.6 (C), 131.2 (CH), 132.1 (CH), 138.3
(CH), 160.0 (C), 188.4 (CH); MS (ESI) m/z 263 (MNa+, 75), 236
(22), 219 (70), 201 (14), 184 (27).
2-Allyloxy-4-chlorobenzaldehyde (6i). The reaction was carried
out as described for the synthesis of 2-allyloxybenzaldehyde (6a) using
4-chloro-2-hydroxybenzaldehyde (5i) (0.936 g, 6.00 mmol). This gave
2-allyloxy-4-chlorobenzaldehyde (6i) (1.17 g, 100%) as a white solid.
Mp 48−49 °C; IR (neat) 2867, 1685, 1589, 1413, 1240, 1222, 996,
904 cm−1; 1H NMR (400 MHz, CDCl3) δ 4.67 (dt, J = 5.2, 1.5 Hz,
2H), 5.39 (dq, J = 10.5, 1.5 Hz, 1H), 5.48 (dq, J = 17.2, 1.5 Hz, 1H),
6.08 (ddt, J = 17.2, 10.5, 5.2 Hz, 1H), 6.95 (d, J = 1.7 Hz, 1H), 7.03
(ddd, J = 8.3, 1.7, 0.7 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 10.46 (d, J =
0.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 69.5 (CH2), 113.5
(CH), 118.6 (CH2), 121.4 (CH), 123.6 (C), 129.5 (CH), 131.7 (CH),
141.8 (C), 161.2 (C), 188.4 (CH); MS (EI) m/z 196 (M+, 44), 181
(9), 167 (38), 155 (100), 126 (25), 99 (27), 75 (14), 63 (26); HRMS
(EI) calcd for C10H9
35ClO2 (M
+), 196.0291, found 196.0288.
2-Allyloxy-4,5-diﬂuorobenzaldehyde (6j). The reaction was
carried out as described for the synthesis of 2-allyloxybenzaldehyde
(6a) using 4,5-diﬂuoro-2-hydroxybenzaldehyde (5j) (0.079 g, 0.500
mmol). This gave 2-allyloxy-4,5-diﬂuorobenzaldehyde (6j) (0.099 g,
100%) as a white solid. Mp 35−36 °C; IR (neat) 2872, 1686, 1604,
1511, 1434, 1323, 1203, 990, 893, 758 cm−1; 1H NMR (500 MHz,
CDCl3) δ 4.63 (dt, J = 5.2, 1.6 Hz, 2H), 5.38 (dq, J = 10.6, 1.6 Hz,
1H), 5.46 (dq, J = 17.3, 1.6 Hz, 1H), 6.05 (ddt, J = 17.3, 10.6, 5.2 Hz,
1H), 6.81 (dd, 3JHF = 11.5,
4JHF = 5.2 Hz, 1H), 7.66 (dd,
3JHF = 11.5,
4JHF = 9.4 Hz, 1H), 10.39 (d,
5JHF = 3.1 Hz, 1H);
13C NMR (126
MHz, CDCl3) δ 70.2 (CH2), 103.0 (d,
2JCF = 21.1 Hz, CH), 116.4
(dd, 2JCF = 18.5,
3JCF = 2.9 Hz, CH), 118.9 (CH2), 121.5 (t,
3JCF = 3.2
Hz, C), 131.6 (CH), 145.2 (dd, 1JCF = 244.6,
2JCF = 13.0 Hz, C), 154.9
(dd, 1JCF = 258.5,
2JCF = 14.5 Hz, C), 157.8 (dd,
3JCF = 8.2,
4JCF = 1.8
Hz, C), 187.2 (CH); MS (EI) m/z 198 (M+, 10), 156 (11), 119 (4),
101 (6), 84 (100); HRMS (EI) calcd for C10H8F2O2 (M
+), 198.0492,
found 198.0489.
2-Allyloxy-3-methoxy-5-nitrobenzaldehyde (6k). The reac-
tion was carried out as described for the synthesis of 2-
allyloxybenzaldehyde (6a) using 2-hydroxy-3-methoxy-5-nitrobenzal-
dehyde (5k) (0.197 g, 1.00 mmol). This gave 2-allyloxy-3-methoxy-5-
nitrobenzaldehyde (6k) (0.209 g, 88%) as a white solid. Mp 82−84
°C; IR (neat) 3101, 2898, 1695, 1684, 1583, 1527, 1480, 1336, 1278,
1230, 1091, 954, 938, 743 cm−1; 1H NMR (500 MHz, CDCl3) δ 4.02
(s, 3H), 4.84 (dt, J = 6.2, 1.3 Hz, 2H), 5.32 (dq, J = 10.3, 1.3 Hz, 1H),
5.38 (dq, J = 17.1, 1.3 Hz, 1H), 6.05 (ddt, J = 17.1, 10.3, 6.2 Hz, 1H),
7.96 (d, J = 2.7 Hz, 1H), 8.33 (d, J = 2.7 Hz, 1H), 10.43 (s, 1H); 13C
NMR (126 MHz, CDCl3) δ 56.6 (CH3), 75.4 (CH2), 111.5 (CH),
115.0 (CH), 120.0 (CH2), 129.3 (C), 132.3 (CH), 143.6 (C), 153.3
(C), 155.8 (C), 188.2 (CH); MS (EI) m/z 237 (M+, 24), 220 (4), 196
(27), 180 (27), 150 (15), 122 (11), 84 (100); HRMS (EI) calcd for
C11H11NO5 (M
+), 237.0637, found 237.0630.
2-Allyloxy-1-naphthaldehyde (6l).32 The reaction was carried
out as described for the synthesis of 2-allyloxybenzaldehyde (6a) using
2-hydroxy-1-naphthaldehyde (5l) (0.172 g, 1.00 mmol). This gave 2-
allyloxy-1-naphthaldehyde (6l) (0.208 g, 98%) as a white solid. Mp
72−74 °C (lit.32 79−80 °C); 1H NMR (400 MHz, CDCl3) δ 4.83 (dt,
J = 5.2, 1.6 Hz, 2H), 5.39 (dq, J = 10.6, 1.6 Hz, 1H), 5.50 (dq, J = 17.3,
1.6 Hz, 1H), 6.13 (ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 7.30 (d, J = 9.3 Hz,
1H), 7.45 (ddd, J = 8.5, 8.4, 1.3 Hz, 1H), 7.65 (ddd, J = 8.5, 8.4, 1.3
Hz, 1H), 7.80 (br d, J = 8.4 Hz, 1H), 8.06 (d, J = 9.3 Hz, 1H), 9.31 (br
d, J = 8.4 Hz, 1H), 10.98 (s, 1H); 13C NMR (101 MHz, CDCl3) δ
69.9 (CH2), 113.7 (CH), 116.8 (C), 118.1 (CH2), 124.7 (CH), 124.9
(CH), 128.3 (CH), 128.5 (C), 129.7 (CH), 131.5 (C), 132.4 (CH),
137.4 (CH), 163.0 (C), 191.8 (CH); MS (ESI) m/z 235 (MNa+, 100),
218 (6), 194 (16).
Ethyl (2E)-3-(2′-Allyloxyphenyl)prop-2-enoate (7a).36 Lithium
bromide (0.47 g, 5.4 mmol) was added to a solution of triethyl
phosphonoacetate (0.91 mL, 4.6 mmol) and 1,8-diazabicyclo[5.4.0]-
undec-7-ene (0.68 mL, 4.6 mmol) in acetonitrile (20 mL) and stirred
at room temperature for 0.5 h. 2-Allyloxybenzaldehyde (6a) (0.22 g,
1.4 mmol) was added, and the solution was stirred at room
temperature for 18 h. The reaction was quenched by the addition of
a saturated solution of ammonium chloride (30 mL), concentrated to
half volume in vacuo, and extracted with diethyl ether (3 × 30 mL).
The combined organic layers were washed with water (100 mL), brine
(100 mL), dried (MgSO4), ﬁltered, and concentrated in vacuo.
Puriﬁcation by column chromatography (elution with 20% diethyl
ether in petroleum ether) gave ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-
enoate (7a) (0.30 g, 95%) as a yellow oil. Spectroscopic data were in
accordance with literature values.36 1H NMR (400 MHz, CDCl3) δ
1.34 (t, J = 7.1 Hz, 3H), 4.26 (q, J = 7.1 Hz, 2H), 4.62 (dt, J = 5.1, 1.5
Hz, 2H), 5.31 (dq, J = 10.6, 1.5 Hz, 1H), 5.43 (dq, J = 17.3, 1.5 Hz,
1H), 6.08 (ddt, J = 17.3, 10.6, 5.1 Hz, 1H), 6.53 (d, J = 16.2 Hz, 1H),
6.90 (d, J = 8.3 Hz, 1H), 6.96 (td, J = 7.7, 0.5 Hz, 1H), 7.29−7.35 (m,
1H), 7.52 (dd, J = 7.7, 1.7 Hz, 1H), 8.05 (d, J = 16.2 Hz, 1H); 13C
NMR (101 MHz, CDCl3) δ 14.4 (CH3), 60.3 (CH2), 69.2 (CH2),
112.5 (CH), 117.7 (CH2), 118.8 (CH), 120.9 (CH), 123.8 (C), 128.8
(CH), 131.3 (CH), 132.9 (CH), 139.9 (CH), 157.3 (C), 167.5 (C);
MS (EI) m/z 232 (M+, 38), 187 (42), 158 (78), 144 (59), 129 (61),
118 (97), 84 (100), 77 (19), 49 (99).
Ethyl (2E)-3-(2′-Allyloxy-6′-methoxyphenyl)prop-2-enoate
(7b). The reaction was carried out as described for the synthesis of
ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-6-
methoxybenzaldehyde (6b) (0.531 g, 2.76 mmol). This gave ethyl
(2E)-3-(2′-allyloxy-6′-methoxyphenyl)prop-2-enoate (7b) (0.594 g,
85%) as a yellow oil. IR (neat) 2979, 1701, 1622, 1593, 1473, 1308,
1254, 1160, 1093 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.33 (t, J = 7.1
Hz, 3H), 3.88 (s, 3H), 4.26 (q, J = 7.1 Hz, 2H), 4.62 (dt, J = 5.1, 1.5
Hz, 2H), 5.30 (dq, J = 10.5, 1.5 Hz, 1H), 5.43 (dq, J = 17.3, 1.5 Hz,
1H), 6.08 (ddt, J = 17.3, 10.5, 5.1 Hz, 1H), 6.54 (d, J = 8.4 Hz, 1H),
6.56 (d, J = 8.4 Hz, 1H), 6.89 (d, J = 16.3 Hz, 1H), 7.23 (t, J = 8.4 Hz,
1H), 8.17 (d, J = 16.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.4
(CH3), 55.7 (CH3), 60.1 (CH2), 69.4 (CH2), 103.8 (CH), 105.0
(CH), 112.5 (C), 117.6 (CH2), 120.8 (CH), 131.1 (CH), 132.9 (CH),
135.4 (CH), 158.9 (C), 160.1 (C), 168.6 (C); MS (ESI) m/z 285
(MNa+, 100); HRMS (ESI) calcd for C15H18NaO4 (MNa
+), 285.1097,
found 285.1088.
Ethyl (2E)-3-(2′-Allyloxy-5′-methoxyphenyl)prop-2-enoate
(7c). The reaction was carried out as described for the synthesis of
ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-5-
methoxybenzaldehyde (6c) (0.580 g, 3.02 mmol). This gave ethyl
(2E)-3-(2′-allyloxy-5′-methoxyphenyl)prop-2-enoate (7c) (0.792 g,
100%) as a yellow oil. IR (neat) 2954, 1706, 1631, 1494, 1214, 1165,
1042, 862 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.34 (t, J = 7.1 Hz,
3H), 3.79 (s, 3H), 4.26 (q, J = 7.1 Hz, 2H), 4.56 (dt, J = 5.2, 1.5 Hz,
2H), 5.29 (dq, J = 10.6, 1.5 Hz, 1H), 5.41 (dq, J = 17.3, 1.5 Hz, 1H),
6.06 (ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 6.49 (d, J = 16.2 Hz, 1H), 6.84
(d, J = 8.8 Hz, 1H), 6.88 (dd, J = 8.8, 2.9 Hz, 1H), 7.05 (d, J = 2.9 Hz,
1H), 8.02 (d, J = 16.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.5
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(CH3), 55.9 (CH3), 60.5 (CH2), 70.2 (CH2), 113.0 (CH), 114.4
(CH), 117.2 (CH), 117.8 (CH2), 119.1 (CH), 124.7 (C), 133.3 (CH),
139.8 (CH), 151.9 (C), 153.8 (C), 167.5 (C); MS (ESI) m/z 285
(MNa+, 100); HRMS (ESI) calcd for C15H18NaO4 (MNa
+), 285.1097,
found 285.1090.
Ethyl (2E)-3-(2′-Allyloxy-4′-methoxyphenyl)prop-2-enoate
(7d). The reaction was carried out as described for the synthesis of
ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-4-
methoxybenzaldehyde (6d) (0.580 g, 3.02 mmol). This gave ethyl
(2E)-3-(2′-allyloxy-4′-methoxyphenyl)prop-2-enoate (7d) (0.79 g,
100%) as a yellow oil. IR (neat) 2980, 1701, 1601, 1505, 1300,
1252, 1155, 986 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.33 (t, J = 7.1
Hz, 3H), 3.82 (s, 3H), 4.24 (q, J = 7.1 Hz, 2H), 4.60 (dt, J = 5.2, 1.5
Hz, 2H), 5.32 (dq, J = 10.5, 1.5 Hz, 1H), 5.43 (dq, J = 17.3, 1.5 Hz,
1H), 6.08 (ddt, J = 17.3, 10.5, 5.2 Hz, 1H), 6.43 (d, J = 16.1 Hz, 1H),
6.44 (d, J = 2.4 Hz, 1H), 6.50 (dd, J = 8.6, 2.4 Hz, 1H), 7.46 (d, J = 8.6
Hz, 1H), 7.96 (d, J = 16.1 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ
14.5 (CH3), 55.6 (CH3), 60.3 (CH2), 69.3 (CH2), 99.7 (CH), 105.6
(CH), 116.3 (C), 117.0 (CH2), 118.1 (CH), 130.3 (CH), 132.9 (CH),
140.0 (CH), 158.8 (C), 162.6 (C), 168.0 (C); MS (ESI) m/z 285
(MNa+, 100); HRMS (ESI) calcd for C15H18NaO4 (MNa
+), 285.1097,
found 285.1090.
Ethyl (2E)-3-(2′-Allyloxy-5′-methylphenyl)prop-2-enoate
(7e). The reaction was carried out as described for the synthesis of
ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-5-
methylbenzaldehyde (6e) (0.167 g, 0.950 mmol). This gave ethyl
(2E)-3-(2′-allyloxy-5′-methylphenyl)prop-2-enoate (7e) (0.206 g,
88%) as a yellow oil. IR (neat) 3021, 1701, 1631, 1494, 1217, 1178,
750 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.33 (t, J = 7.1 Hz, 3H),
2.29 (s, 3H), 4.25 (q, J = 7.1 Hz, 2H), 4.59 (dt, J = 5.2, 1.6 Hz, 2H),
5.29 (dq, J = 10.6, 1.6 Hz, 1H), 5.41 (dq, J = 17.3, 1.6 Hz, 1H), 6.07
(ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 6.51 (d, J = 16.2 Hz, 1H), 6.80 (d, J =
8.4 Hz, 1H), 7.11 (dd, J = 8.4, 2.0 Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H),
8.01 (d, J = 16.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 14.4
(CH3), 20.4 (CH3), 60.3 (CH2), 69.4 (CH2), 112.6 (CH), 117.6
(CH2), 118.6 (CH), 123.5 (C), 129.2 (CH), 130.1 (C), 131.8 (CH),
133.1 (CH), 140.0 (CH), 155.3 (C), 167.5 (C); MS (ESI) m/z 269
(MNa+, 100); HRMS (ESI) calcd for C15H18NaO3 (MNa
+), 269.1148,
found 269.1139.
Ethyl (2E)-3-(2′-Allyloxy-5′-nitrophenyl)prop-2-enoate (7f).
The reaction was carried out as described for the synthesis of ethyl
(2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-5-nitro-
benzaldehyde (6f) (0.049 g, 0.24 mmol). This gave ethyl (2E)-3-(2′-
allyloxy-5′-nitrophenyl)prop-2-enoate (7f) (0.060 g, 91%) as a white
solid. Mp 64−65 °C; IR (neat) 2986, 1690, 1631, 1580, 1512, 1341,
1273, 1150, 1032, 872 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.35 (t, J
= 7.1 Hz, 3H), 4.29 (q, J = 7.1 Hz, 2H), 4.74 (dt, J = 5.2, 1.5 Hz, 2H),
5.39 (dq, J = 10.6, 1.5 Hz, 1H), 5.45 (dq, J = 17.3, 1.5 Hz, 1H), 6.07
(ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 6.61 (d, J = 16.2 Hz, 1H), 6.98 (d, J =
9.2 Hz, 1H), 7.98 (d, J = 16.2 Hz, 1H), 8.22 (dd, J = 9.2, 2.8 Hz, 1H),
8.43 (d, J = 2.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.3 (CH3),
60.7 (CH2), 70.0 (CH2), 112.2 (CH), 118.9 (CH2), 121.5 (CH),
124.0 (CH), 124.3 (C), 126.6 (CH), 131.5 (CH), 137.3 (CH), 141.4
(C), 161.4 (C), 166.5 (C); MS (ESI) m/z 300 (MNa+, 100); HRMS
(ESI) calcd for C14H15NNaO5 (MNa
+), 300.0842, found 300.0829.
Ethyl (2E)-3-(2′-Allyloxy-5′-chlorophenyl)prop-2-enoate
(7g). The reaction was carried out as described for the synthesis of
ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-5-
chlorobenzaldehyde (6g) (0.595 g, 3.02 mmol). This gave ethyl (2E)-
3-(2′-allyloxy-5′-chlorophenyl)prop-2-enoate (7g) (0.743 g, 92%) as a
yellow oil. IR (neat) 2982, 1705, 1632, 1481, 1314, 1248, 1165, 1034,
984 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.33 (t, J = 7.1 Hz, 3H),
4.26 (q, J = 7.1 Hz, 2H), 4.60 (dt, J = 5.2, 1.4 Hz, 2H), 5.32 (dq, J =
10.5, 1.4 Hz, 1H), 5.41 (dq, J = 17.3, 1.4 Hz, 1H), 6.05 (ddt, J = 17.3,
10.5, 5.2 Hz, 1H), 6.49 (d, J = 16.2 Hz, 1H), 6.83 (d, J = 8.9 Hz, 1H),
7.25 (dd, J = 8.9, 2.5 Hz, 1H), 7.48 (d, J = 2.5 Hz, 1H), 7.95 (d, J =
16.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.5 (CH3), 60.6
(CH2), 69.7 (CH2), 114.0 (CH), 118.2 (CH2), 120.1 (CH), 125.4
(C), 126.1 (C), 128.3 (CH), 130.8 (CH), 132.6 (CH), 138.6 (CH),
155.8 (C), 167.2 (C); MS (ESI) m/z 289 (MNa+, 100); HRMS (ESI)
calcd for C14H15
35ClNaO3 (MNa
+), 289.0602, found 289.0610.
Ethyl (2E)-3-(2′-Allyloxy-5′-bromophenyl)prop-2-enoate
(7h). The reaction was carried out as described for the synthesis of
ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-5-
bromobenzaldehyde (6h) (0.545 g, 2.26 mmol). This gave ethyl (2E)-
3-(2′-allyloxy-5′-bromophenyl)prop-2-enoate (7h) (0.685 g, 97%) as a
white solid. Mp <30 °C; IR (neat) 2986, 1688, 1628, 1489, 1300,
1275, 1175, 986 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.33 (t, J = 7.1
Hz, 3H), 4.26 (q, J = 7.1 Hz, 2H), 4.60 (dt, J = 5.2, 1.4 Hz, 2H), 5.32
(dq, J = 10.6, 1.4 Hz, 1H), 5.41 (dq, J = 17.3, 1.4 Hz, 1H), 6.05 (ddt, J
= 17.3, 10.6, 5.2 Hz, 1H), 6.49 (d, J = 16.2 Hz, 1H), 6.78 (d, J = 8.8
Hz, 1H), 7.39 (dd, J = 8.8, 2.5 Hz, 1H), 7.62 (d, J = 2.5 Hz, 1H), 7.94
(d, J = 16.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.5 (CH3),
60.6 (CH2), 69.6 (CH2), 113.3 (C), 114.4 (CH), 118.3 (CH2), 120.2
(CH), 125.9 (C), 131.2 (CH), 132.6 (CH), 133.8 (CH), 138.5 (CH),
156.3 (C), 167.2 (C); MS (ESI) m/z 333 (MNa+, 100); HRMS (ESI)
calcd for C14H15
79BrNaO3 (MNa
+), 333.0097, found 333.0090.
Ethyl (2E)-3-(2′-Allyloxy-4′-chlorophenyl)prop-2-eneoate
(7i). The reaction was carried out as described for the synthesis of
ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-4-
chlorobenzaldehyde (6i) (0.150 g, 0.760 mmol). This gave ethyl (2E)-
3-(2′-allyloxy-4′-chlorophenyl)prop-2-enoate (7i) (0.192 g, 94%) as
an oil. IR (neat) 2989, 1707, 1632, 1592, 1486, 1312, 1178, 908, 732
cm−1; 1H NMR (500 MHz, CDCl3) δ 1.35 (t, J = 7.1 Hz, 3H), 4.27 (q,
J = 7.1 Hz, 2H), 4.63 (dt, J = 5.2, 1.3 Hz, 2H), 5.36 (dq, J = 17.2, 1.3
Hz, 1H), 5.46 (dq, J = 10.6, 1.3 Hz, 1H), 6.08 (ddt, J = 17.2, 10.6, 5.2
Hz, 1H), 6.51 (d, J = 16.2 Hz, 1H), 6.91 (d, J = 1.9 Hz, 1H), 6.97 (dd,
J = 8.3, 1.9 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.96 (d, J = 16.2 Hz,
1H); 13C NMR (126 MHz, CDCl3) δ 14.3 (CH3), 60.4 (CH2), 69.5
(CH2), 113.1 (CH), 118.2 (CH2), 119.2 (CH), 121.1 (CH), 122.4
(C), 129.5 (CH), 132.2 (CH), 136.7 (C), 138.7 (CH), 157.6 (C),
167.2 (C); MS (ESI) m/z 289 (MNa+, 100); HRMS (ESI) calcd for
C14H15
35ClNaO3 (MNa
+), 289.0602, found 289.0595.
Ethyl (2E)-3-(2′-Allyloxy-4′,5′-diﬂuorophenyl)prop-2-enoate
(7j). The reaction was carried out as described for the synthesis of
ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-
4,5-diﬂuorobenzaldehyde (6j) (0.093 g, 0.470 mmol). This gave ethyl
(2E)-3-(2′-allyloxy-4′,5′-diﬂuorophenyl)prop-2-enoate (7j) (0.117 g,
93%) as a white solid. Mp 52−53 °C; IR (neat) 2985, 1690, 1599,
1511, 1273, 1224, 1174, 987, 857 cm−1; 1H NMR (500 MHz, CDCl3)
δ 1.33 (t, J = 7.1 Hz, 3H), 4.26 (q, J = 7.1 Hz, 2H), 4.57 (dt, J = 5.2,
1.6 Hz, 2H), 5.34 (dq, J = 10.6, 1.6 Hz, 1H), 5.43 (dq, J = 17.3, 1.6 Hz,
1H), 6.04 (ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 6.41 (d, J = 16.2 Hz, 1H),
6.72 (dd, 3JHF = 11.5,
4JHF = 5.2 Hz, 1H), 7.32 (dd,
3JHF = 11.5,
4JHF =
9.0 Hz, 1H), 7.91 (dd, J = 16.2, 5JHF = 1.0 Hz, 1H);
13C NMR (101
MHz, CDCl3) δ 14.3 (CH3), 60.5 (CH2), 70.2 (CH2), 102.6 (d,
2JCF =
20.9 Hz, CH), 116.2 (dd, 2JCF = 18.6,
3JCF = 1.8 Hz, CH), 118.5
(CH2), 119.5 (CH), 120.1 (dd,
3JCF = 5.8,
4JCF = 4.3 Hz, C), 132.1
(CH), 137.7 (CH), 144.8 (dd, 1JCF = 241.6,
2JCF = 13.1 Hz, C), 151.5
(dd, 1JCF = 253.1,
2JCF = 14.0 Hz, C), 153.7 (dd,
3JCF = 7.3,
4JCF = 1.6
Hz, C), 167.0 (C); MS (ESI) m/z 291 (MNa+, 100); HRMS (ESI)
calcd for C14H14F2NaO3 (MNa
+), 291.0803, found 291.0797.
Ethyl (2E)-3-(2′-Allyloxy-3′-methoxy-5′-nitrophenyl)prop-2-
enoate (7k). The reaction was carried out as described for the
synthesis of ethyl (2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using
2-allyloxy-3-methoxy-5-nitrobenzaldehyde (6k) (0.617 g, 2.60 mmol).
This gave ethyl (2E)-3-(2′-allyloxy-3′-methoxy-5′-nitrophenyl)prop-2-
enoate (7k) (0.798 g, 100%) as a white solid. Mp 82−83 °C; IR (neat)
3022, 1711, 1641, 1582, 1527, 1466, 1340, 1278, 1179, 979 cm−1; 1H
NMR (500 MHz, CDCl3) δ 1.35 (t, J = 7.1 Hz, 3H), 3.97 (s, 3H), 4.28
(q, J = 7.1 Hz, 2H), 4.69 (dt, J = 6.1, 1.3 Hz, 2H), 5.28 (dq, J = 10.3,
1.3 Hz, 1H), 5.37 (dq, J = 17.2, 1.3 Hz, 1H), 6.05 (ddt, J = 17.2, 10.3,
6.1 Hz, 1H), 6.56 (d, J = 16.2 Hz, 1H), 7.77 (d, J = 2.6 Hz, 1H), 7.99
(d, J = 16.2 Hz, 1H), 8.10 (d, J = 2.6 Hz, 1H); 13C NMR (126 MHz,
CDCl3) δ 14.2 (CH3), 56.4 (CH3), 60.7 (CH2), 74.8 (CH2), 108.0
(CH), 114.9 (CH), 119.2 (CH2), 121.9 (CH), 129.1 (C), 132.9 (CH),
137.5 (CH), 143.7 (C), 151.8 (C), 153.1 (C), 166.3 (C); MS (ESI)
m/z 330 (MNa+, 100); HRMS (ESI) calcd for C15H17NNaO6
(MNa+), 330.0948, found 330.0934.
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Ethyl (2E)-3-(2′-Allyloxynaphthalen-1′-yl)prop-2-enoate (7l).
The reaction was carried out as described for the synthesis of ethyl
(2E)-3-(2′-allyloxyphenyl)prop-2-enoate (7a) using 2-allyloxy-1-naph-
thaldehyde (6l) (0.620 g, 2.94 mmol). This gave ethyl (2E)-3-(2′-
allyloxynaphthalen-1′-yl)prop-2-enoate (7l) (0.760 g, 92%) as a white
solid. Mp 46−48 °C; IR (neat) 2981, 1701, 1617, 1264, 1159, 907,
727 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.37 (t, J = 7.1 Hz, 3H),
4.32 (q, J = 7.1 Hz, 2H), 4.75 (dt, J = 5.2, 1.6 Hz, 2H), 5.31 (dq, J =
10.6, 1.6 Hz, 1H), 5.44 (dq, J = 17.3, 1.6 Hz, 1H), 6.10 (ddt, J = 17.3,
10.6, 5.2 Hz, 1H), 6.77 (d, J = 16.2 Hz, 1H), 7.25 (d, J = 9.3 Hz, 1H),
7.38 (ddd, J = 8.5, 8.4, 1.0 Hz, 1H), 7.52 (ddd, J = 8.5, 8.4, 1.0 Hz,
1H), 7.78 (dd, J = 8.4, 1.0 Hz, 1H), 7.81 (d, J = 9.3 Hz, 1H), 8.19 (dd,
J = 8.4, 1.0 Hz, 1H), 8.36 (d, J = 16.2 Hz, 1H); 13C NMR (101 MHz,
CDCl3) δ 14.4 (CH3), 60.4 (CH2), 70.0 (CH2), 114.3 (CH), 117.4
(C), 117.8 (CH2), 123.5 (CH), 123.7 (CH), 124.0 (CH), 127.3 (CH),
128.5 (CH), 129.1 (C), 131.3 (CH), 132.8 (C), 133.0 (CH), 137.7
(CH), 155.6 (C), 167.8 (C); MS (ESI) m/z 305 (MNa+, 100); HRMS
(ESI) calcd for C18H18NaO3 (MNa
+), 305.1148, found 305.1139.
(2E)-3-(2′-Allyloxyphenyl)prop-2-en-1-ol (8a).36 Diisobutylalu-
minum hydride (3.21 mL, 1 M solution in hexanes) was added
dropwise with stirring to a solution of ethyl (2E)-3-(2′-vinylphenyl)-
prop-2-enoate (7a) (0.298 g, 1.28 mmol) in diethyl ether (30 mL) at
−78 °C. The solution was stirred at −78 °C for 3 h, then allowed to
return to room temperature over 15 h. The reaction was quenched
with 10% aqueous potassium sodium tartrate solution (30 mL),
extracted with diethyl ether (2 × 20 mL), washed with water (100
mL), brine (100 mL), dried (MgSO4), ﬁltered, and concentrated in
vacuo. Puriﬁcation by column chromatography (elution with 30%
diethyl ether in petroleum ether) gave (2E)-3-(2′-allyloxyphenyl)prop-
2-en-1-ol (8a) (0.211 g, 87%) as a white solid. Mp 44−46 °C;
spectroscopic data were in accordance with literature values.36 1H
NMR (400 MHz, CDCl3) δ 1.41 (t, J = 5.9 Hz, 1H), 4.33 (td, J = 5.9,
0.8 Hz, 2H), 4.58 (dt, J = 5.2, 1.5 Hz, 2H), 5.29 (dq, J = 10.5, 1.5 Hz,
1H), 5.42 (dq, J = 17.3, 1.5 Hz, 1H), 6.08 (ddt, J = 17.3, 10.5, 5.2 Hz,
1H), 6.40 (dt, J = 16.0, 5.9 Hz, 1H), 6.87 (dd, J = 8.2, 0.8 Hz, 1H),
6.91−7.02 (m, 2H), 7.21 (ddd, J = 8.2, 7.5, 1.7 Hz, 1H), 7.46 (dd, J =
7.5, 1.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 64.5 (CH2), 69.4
(CH2), 112.5 (CH), 117.6 (CH2), 121.1 (CH), 126.2 (C), 126.4
(CH), 127.2 (CH), 128.8 (CH), 129.3 (CH), 133.5 (CH), 156.0 (C);
MS (EI) m/z 190 (M+, 57), 149 (59), 131 (92), 121 (60), 119 (46),
91 (100), 77 (40).
(2E)-3-(2′-Allyloxy-6′-methoxyphenyl)prop-2-en-1-ol (8b).
The reaction was carried out as described for the synthesis of (2E)-
3-(2′-allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-
allyloxy-6′-methoxyphenyl)prop-2-enoate (7b) (0.569 g, 2.17 mmol).
This gave (2E)-3-(2′-allyloxy-6′-methoxyphenyl)prop-2-en-1-ol (8b)
(0.427 g, 90%) as a colorless oil. IR (neat) 3372, 2953, 1584, 1470,
1251, 1200, 1112, 1079 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.41 (t,
J = 5.9 Hz, 1H), 3.85 (s, 3H), 4.33 (td, J = 5.9, 1.0 Hz, 2H), 4.58 (dt, J
= 5.2, 1.5 Hz, 2H), 5.28 (dq, J = 10.5, 1.5 Hz, 1H), 5.42 (dq, J = 17.3,
1.5 Hz, 1H), 6.08 (ddt, J = 17.3, 10.5, 5.2 Hz, 1H), 6.55 (d, J = 8.3 Hz,
1H), 6.56 (d, J = 8.3 Hz, 1H), 6.82 (dt, J = 16.2, 5.9 Hz, 1H), 6.92 (br
d, J = 16.2 Hz, 1H), 7.13 (t, J = 8.3 Hz, 1H); 13C NMR (126 MHz,
CDCl3) δ 55.8 (CH3), 65.7 (CH2), 69.6 (CH2), 104.1 (CH), 105.4
(CH), 114.4 (C), 117.6 (CH2), 122.0 (CH), 128.3 (CH), 132.8 (CH),
133.5 (CH), 157.6 (C), 158.7 (C); MS (ESI) m/z 243 (MNa+, 100);
HRMS (ESI) calcd for C13H16NaO3 (MNa
+), 243.0992, found
243.0987.
(2E)-3-(2′-Allyloxy-5′-methoxyphenyl)prop-2-en-1-ol (8c).
The reaction was carried out as described for the synthesis of (2E)-
3-(2′-allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-
allyloxy-5′-methoxyphenyl)prop-2-enoate (7c) (0.126 g, 2.94 mmol).
This gave (2E)-3-(2′-allyloxy-5′-methoxyphenyl)prop-2-en-1-ol (8c)
(0.534 g, 83%) as a white solid. Mp 41−43 °C; IR (neat) 3387, 2915,
1585, 1493, 1424, 1213, 1123, 1011 cm−1; 1H NMR (500 MHz,
CDCl3) δ 1.48 (br s, 1H), 3.78 (s, 3H), 4.33 (br d, J = 5.7 Hz, 2H),
4.51 (dt, J = 5.2, 1.5 Hz, 2H), 5.27 (dq, J = 10.5, 1.5 Hz, 1H), 5.40 (dq,
J = 17.3, 1.5 Hz, 1H), 6.06 (ddt, J = 17.3, 10.5, 5.2 Hz, 1H), 6.38 (dt, J
= 16.0, 5.7 Hz, 1H), 6.75 (dd, J = 8.9, 3.0 Hz, 1H), 6.81 (d, J = 8.9 Hz,
1H), 6.94 (dt, J = 16.0, 1.3 Hz, 1H), 7.01 (d, J = 3.0 Hz, 1H); 13C
NMR (126 MHz, CDCl3) δ 55.9 (CH3), 64.3 (CH2), 70.3 (CH2),
112.2 (CH), 114.0 (CH), 114.3 (CH), 117.5 (CH2), 126.2 (CH),
127.2 (C), 129.6 (CH), 133.7 (CH), 150.4 (C), 154.0 (C); MS (ESI)
m/z 243 (MNa+, 100); HRMS (ESI) calcd for C13H16NaO3 (MNa
+),
243.0992, found 243.0990.
(2E)-3-(2′-Allyloxy-4′-methoxyphenyl)prop-2-en-1-ol (8d).
The reaction was carried out as described for the synthesis of (2E)-
3-(2′-allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-
allyloxy-4′-methoxyphenyl)prop-2-enoate (7d) (0.676 g, 2.58 mmol).
This gave (2E)-3-(2′-allyloxy-4′-methoxyphenyl)prop-2-en-1-ol (8d)
(0.566 g, 100%) as a white solid. Mp <30 °C; IR (neat) 3379, 2914,
1609, 1576, 1500, 1420, 1261, 1197, 1003 cm−1; 1H NMR (500 MHz,
CDCl3) δ 1.89 (s, 1H), 3.78 (s, 3H), 4.28 (dd, J = 6.1, 1.2 Hz, 2H),
4.53 (d, J = 5.2 Hz, 2H), 5.28 (dd, J = 10.5, 1.5 Hz, 1H), 5.41 (dd, J =
17.3, 1.5 Hz, 1H), 6.06 (ddt, J = 17.3, 10.5, 5.2 Hz, 1H), 6.27 (dt, J =
16.0, 6.1 Hz, 1H), 6.42 (d, J = 2.4 Hz, 1H), 6.47 (dd, J = 8.5, 2.4 Hz,
1H), 6.86 (br d, J = 16.0 Hz, 1H), 7.35 (d, J = 8.5 Hz, 1H); 13C (126
MHz, CDCl3) δ 55.4 (CH3), 64.5 (CH2), 69.2 (CH2), 99.7 (CH),
105.3 (CH), 117.7 (CH2), 119.1 (C), 126.2 (CH), 127.1 (CH), 127.8
(CH), 133.2 (CH), 156.9 (C), 160.4 (C); MS (CI) m/z 221 (MH+,
18), 203 (100), 177 (3), 163 (2), 81 (5), 69 (7); HRMS (CI) calcd for
C13H17O3 (MH
+), 221.1178, found 221.1177.
(2E)-3-(2′-Allyloxy-5′-methylphenyl)prop-2-en-1-ol (8e). The
reaction was carried out as described for the synthesis of (2E)-3-(2′-
allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-allyloxy-5′-
methylphenyl)prop-2-enoate (7e) (0.198 g, 0.750 mmol). This gave
(2E)-3-(2′-allyloxy-5′-methylphenyl)prop-2-en-1-ol (8e) (0.164 g,
100%) as a colorless oil. IR (neat) 3370, 2922, 1494, 1243, 1220,
997, 909 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.39 (br s, 1H), 2.29
(s, 3H), 4.32 (d, J = 5.2 Hz, 2H), 4.54 (dt, J = 5.2, 1.6 Hz, 2H), 5.27
(dq, J = 10.6, 1.6 Hz, 1H), 5.40 (dq, J = 17.3, 1.6 Hz, 1H), 6.07 (ddt, J
= 17.3, 10.6, 5.2 Hz, 1H), 6.38 (dt, J = 16.2, 5.2 Hz, 1H), 6.76 (d, J =
8.3 Hz, 1H), 6.94 (d, J = 16.2 Hz, 1H), 7.00 (dd, J = 8.3, 2.1 Hz, 1H),
7.27 (d, J = 2.1 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 20.6 (CH3),
64.2 (CH2), 69.4 (CH2), 112.5 (CH), 117.4 (CH2), 125.8 (C), 126.1
(CH), 127.6 (CH), 129.1 (2 × CH), 130.1 (C), 133.6 (CH), 153.8
(C); MS (EI) m/z 204 (M+, 49), 163 (31), 145 (61), 133 (64), 105
(97), 84 (100), 77 (24), 69 (13); HRMS (EI) calcd for C13H16O2
(M+), 204.1150, found 204.1153.
(2E)-3-(2′-Allyloxy-5′-nitrophenyl)prop-2-en-1-ol (8f). The
reaction was carried out as described for the synthesis of (2E)-3-(2′-
allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-allyloxy-5′-
nitrophenyl)prop-2-enoate (7f) (0.629 g, 2.27 mmol). This gave (2E)-
3-(2′-allyloxy-5′-nitrophenyl)prop-2-en-1-ol (8f) (0.469 g, 88%) as a
yellow solid. Mp 62−66 °C; IR (neat) 2864, 1611, 1508, 1335, 1246,
1078, 990 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.89 (br s, 1H), 4.37
(dd, J = 5.4, 1.7 Hz, 2H), 4.67 (dt, J = 5.2, 1.5 Hz, 2H), 5.35 (dq, J =
10.6, 1.5 Hz, 1H), 5.43 (dq, J = 17.3, 1.5 Hz, 1H), 6.05 (ddt, J = 17.3,
10.6, 5.2 Hz, 1H), 6.49 (dt, J = 16.2, 5.4 Hz, 1H), 6.88 (d, J = 9.2 Hz,
1H), 6.92 (dt, J = 16.2, 1.7 Hz, 1H), 8.08 (dd, J = 9.2, 2.8 Hz, 1H),
8.30 (d, J = 2.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 63.7 (CH2),
69.8 (CH2), 111.6 (CH), 118.8 (CH2), 122.6 (CH), 123.6 (CH),
124.5 (CH), 127.0 (C), 132.0 (CH), 132.3 (CH), 141.5 (C), 160.3
(C); MS (ESI) m/z 258 (MNa+, 100); HRMS (ESI) calcd for
C12H13NNaO4 (MNa
+), 258.0737, found 258.0737.
(2E)-3-(2′-Allyloxy-5′-chlorophenyl)prop-2-en-1-ol (8g). The
reaction was carried out as described for the synthesis of (2E)-3-(2′-
allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-allyloxy-5′-
chlorophenyl)prop-2-enoate (7g) (0.126 g, 0.472 mmol). This gave
(2E)-3-(2′-allyloxy-5′-chlorophenyl)prop-2-en-1-ol (8g) (0.101 g,
95%) as a yellow oil. IR (neat) 3336, 2918, 1592, 1481, 1242, 1129,
1015, 970 cm−1; 1H NMR (500 MHz, CDCl3) δ 2.24 (br s, 1H), 4.30
(dd, J = 5.7, 1.5 Hz, 2H), 4.51 (dt, J = 5.2, 1.4 Hz, 2H), 5.28 (dq, J =
10.6, 1.4 Hz, 1H), 5.39 (dq, J = 17.3, 1.4 Hz, 1H), 6.03 (ddt, J = 17.3,
10.6, 5.2 Hz, 1H), 6.34 (dt, J = 16.1, 5.7 Hz, 1H), 6.74 (d, J = 8.8 Hz,
1H), 6.87 (dt, J = 16.1, 1.5 Hz, 1H), 7.11 (dd, J = 8.8, 2.6 Hz, 1H),
7.37 (d, J = 2.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 63.8 (CH2),
69.6 (CH2), 113.7 (CH), 117.8 (CH2), 124.7 (CH), 126.0 (C), 126.7
(CH), 127.8 (C), 128.1 (CH), 130.7 (CH), 133.0 (CH), 154.3 (C);
MS (EI) m/z 224 (M+, 100), 183 (58), 165 (89), 155 (78), 125 (86),
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91 (36), 63 (12); HRMS (EI) calcd for C12H13
35ClO2 (M
+), 224.0604,
found 224.0606.
(2E)-3-(2′-Allyloxy-5′-bromophenyl)prop-2-en-1-ol (8h). The
reaction was carried out as described for the synthesis of (2E)-3-(2′-
allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-allyloxy-5′-
bromophenyl)prop-2-enoate (7h) (0.075 g, 0.24 mmol). This gave
(2E)-3-(2′-allyloxy-5′-bromophenyl)prop-2-en-1-ol (8h) (0.058 g,
90%) as a white solid. Mp <30 °C; IR (neat) 3297, 2857, 1588,
1482, 1249, 1127, 1016, 974 cm−1; 1H NMR (500 MHz, CDCl3) δ
2.07 (s, 1H), 4.30 (dd, J = 5.7, 1.4 Hz, 2H), 4.51 (dt, J = 5.2, 1.3 Hz,
2H), 5.28 (dq, J = 10.5, 1.3 Hz, 1H), 5.38 (dq, J = 17.2, 1.3 Hz, 1H),
6.03 (ddt, J = 17.2, 10.5, 5.2 Hz, 1H), 6.34 (dt, J = 16.1, 5.7 Hz, 1H),
6.70 (d, J = 8.8 Hz, 1H), 6.86 (dt, J = 16.1, 1.4 Hz, 1H), 7.25 (dd, J =
8.8, 2.5 Hz, 1H), 7.52 (d, J = 2.5 Hz, 1H); 13C NMR (126 MHz,
CDCl3) δ 63.9 (CH2), 69.5 (CH2), 113.4 (C), 114.1 (CH), 117.9
(CH2), 124.6 (CH), 128.3 (C), 129.6 (CH), 130.7 (CH), 131.1 (CH),
133.0 (CH), 154.8 (C); MS (EI) m/z 268 (M+, 65), 229 (40), 199
(50), 131 (20), 118 (100), 91 (27), 63 (11); HRMS (EI) calcd for
C12H13
79BrO2 (M
+), 268.0099, found 268.0101.
(2E)-3-(2′-Allyloxy-4′-chlorophenyl)prop-2-en-1-ol (8i). The
reaction was carried out as described for the synthesis of (2E)-3-(2′-
allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-allyloxy-4′-
chlorophenyl)prop-2-enoate (7i) (0.193 g, 0.720 mmol). This gave
(2E)-3-(2′-allyloxy-4′-chlorophenyl)prop-2-en-1-ol (8i) (0.138 g,
85%) as a white solid. Mp 45−47 °C; IR (neat) 3350, 2869, 1590,
1485, 1408, 1245, 1226, 1015, 998, 972, 905, 730 cm−1; 1H NMR (400
MHz, CDCl3) δ 1.59 (t, J = 5.1 Hz, 1H), 4.34 (br t, J = 5.1 Hz, 2H),
4.57 (dt, J = 5.2, 1.4 Hz, 2H), 5.33 (dq, J = 10.6, 1.4 Hz, 1H), 5.44 (dq,
J = 17.2, 1.4 Hz, 1H), 6.07 (ddt, J = 17.2, 10.6, 5.2 Hz, 1H), 6.38 (dt, J
= 16.0, 5.1 Hz, 1H), 6.86 (d, J = 1.8 Hz, 1H), 6.88−6.94 (m, 2H), 7.37
(d, J = 8.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 64.1 (CH2), 69.4
(CH2), 112.9 (CH), 118.0 (CH2), 121.0 (CH), 124.6 (C), 125.2
(CH), 127.7 (CH), 129.6 (CH), 132.6 (CH), 133.8 (C), 156.2 (C);
MS (EI) m/z 224 (M+, 93), 183 (99), 165 (73), 155 (100), 125 (55),
120 (10), 91 (48), 77 (14); HRMS (EI) calcd for C12H13
35ClO2 (M
+),
224.0604, found 224.0600.
(2E)-3-(2′-Allyloxy-4′,5′-diﬂuorophenyl)prop-2-en-1-ol (8j).
The reaction was carried out as described for the synthesis of (2E)-
3-(2′-allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-
allyloxy-4′,5′-diﬂuoro-phenyl)prop-2-enoate (7j) (0.090 g, 0.340
mmol). This gave (2E)-3-(2′-allyloxy-4′,5′-diﬂuorophenyl)prop-2-en-
1-ol (8j) (0.071 g, 94%) as a yellow oil. IR (neat) 3341, 2867, 1610,
1507, 1422, 1192, 991, 969 cm−1; 1H NMR (400 MHz, CDCl3) δ 1.57
(br s, 1H), 4.32 (br d, J = 5.2 Hz, 2H), 4.51 (dt, J = 5.2, 1.6 Hz, 2H),
5.31 (dq, J = 10.6, 1.6 Hz, 1H), 5.41 (dq, J = 17.3, 1.6 Hz, 1H), 6.03
(ddt, J = 17.3, 10.6, 5.2 Hz, 1H), 6.28 (dt, J = 16.0, 5.2 Hz, 1H), 6.67
(dd, 3JHF = 11.5,
4JHF = 5.2 Hz, 1H), 6.85 (dd, J = 16.0, 1.6 Hz, 1H),
7.23 (dd, 3JHF = 11.5,
4JHF = 9.0 Hz, 1H);
13C NMR (101 MHz,
CDCl3) δ 63.9 (CH2), 70.1 (CH2), 102.5 (d,
2JCF = 20.8 Hz, CH),
114.7 (dd, 2JCF = 18.3,
3JCF = 1.4 Hz, CH), 118.1 (CH2), 122.5 (dd,
3JCF = 5.1,
4JCF = 3.8 Hz, C), 124.2 (CH), 129.9 (d,
4JCF = 2.2 Hz,
CH), 132.6 (CH), 144.8 (dd, 1JCF = 240.5,
2JCF = 13.0 Hz, C), 149.7
(dd, 1JCF = 248.7,
2JCF = 13.9 Hz, C), 151.8 (dd,
3JCF = 7.1,
4JCF = 1.8
Hz, C); MS (EI) m/z 226 (M+, 79), 185 (74), 167 (100), 157 (60),
127 (94), 119 (22), 84 (97); HRMS (EI) calcd for C12H12F2O2 (M
+),
226.0805, found 226.0806.
(2E)-3-(2′-Allyloxy-3′-methoxy-5′-nitrophenyl)prop-2-en-1-
ol (8k). The reaction was carried out as described for the synthesis of
(2E)-3-(2′-allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-
allyloxy-3′-methoxy-5′-nitrophenyl)prop-2-enoate (7k) (0.798 g, 2.59
mmol). This gave (2E)-3-(2′-allyloxy-3′-methoxy-5′-nitrophenyl)-
prop-2-en-1-ol (8k) (0.604 g, 88%) as a white solid. Mp 58−60 °C;
IR (neat) 3267, 2933, 1657, 1579, 1511, 1471, 1336, 1265, 1210, 1104,
1071, 977 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.59 (t, J = 5.6 Hz,
1H), 3.95 (s, 3H), 4.38 (td, J = 5.6, 1.6 Hz, 2H), 4.60 (dt, J = 6.0, 1.3
Hz, 2H), 5.26 (dq, J = 10.5, 1.3 Hz, 1H), 5.37 (dq, J = 17.1, 1.3 Hz,
1H), 6.06 (ddt, J = 17.1, 10.5, 6.0 Hz, 1H), 6.50 (dt, J = 16.2, 5.6 Hz,
1H), 6.95 (dt, J = 16.2, 1.6 Hz, 1H), 7.66 (d, J = 2.6 Hz, 1H), 8.04 (d,
J = 2.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 56.2 (CH3), 63.4
(CH2), 74.4 (CH2), 105.9 (CH), 114.1 (CH), 118.6 (CH2), 123.4
(CH), 131.5 (C), 132.7 (CH), 133.3 (CH), 143.8 (C), 150.3 (C),
153.0 (C); MS (ESI) m/z 288 (MNa+, 100); HRMS (ESI) calcd for
C13H15NNaO5 (MNa
+), 288.0842, found 288.0837.
(2E)-3-(2′-Allyloxynaphthalen-1′-yl)prop-2-en-1-ol (8l). The
reaction was carried out according to the procedure described for the
synthesis of (2E)-3-(2′-allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl
(2E)-3-(2′-allyloxynaphthalen-1′-yl)prop-2-enoate (7l) (0.760 g, 2.69
mmol). This gave (2E)-3-(2′-allyloxynaphthalen-1′-yl)prop-2-en-1-ol
(8l) (0.592 g, 92%) as a yellow solid. Mp 56−58 °C; IR (neat) 3391,
2865, 1591, 1510, 1217, 1011, 805 cm−1; 1H NMR (500 MHz,
CDCl3) δ 1.52 (t, J = 6.0 Hz, 1H), 4.47 (td, J = 6.0, 1.6 Hz, 2H), 4.70
(dt, J = 5.2, 1.6 Hz, 2H), 5.29 (dq, J = 10.5, 1.6 Hz, 1H), 5.44 (dq, J =
17.3, 1.6 Hz, 1H), 6.10 (ddt, J = 17.3, 10.5, 5.2 Hz, 1H), 6.46 (dt, J =
16.2, 6.0 Hz, 1H), 7.04 (dt, J = 16.2, 1.6 Hz, 1H), 7.25 (d, J = 9.0 Hz,
1H), 7.35 (ddd, J = 8.5, 8.4, 1.0 Hz, 1H), 7.46 (ddd, J = 8.5, 8.4, 1.0
Hz, 1H), 7.74 (d, J = 9.0 Hz, 1H), 7.78 (dd, J = 8.4, 1.0 Hz, 1H), 8.16
(dd, J = 8.4, 1.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 64.4 (CH2),
70.2 (CH2), 114.9 (CH), 117.5 (CH2), 120.7 (C), 123.7 (CH), 123.9
(CH), 124.3 (CH), 126.5 (CH), 128.3 (CH), 128.8 (CH), 129.4 (C),
132.6 (C), 133.6 (CH), 135.3 (CH), 153.5 (C); MS (EI) m/z 240
(M+, 40), 199 (25), 181 (56), 169 (93), 141 (100), 115 (38), 83 (95),
69 (10); HRMS (EI) calcd for C16H16O2 (M
+), 240.1150, found
240.1153.
5-(2′,2′,2′-Trichloromethylcarbonylamino)-2,5-dihydro-1-
benzoxepine (11a). (2E)-3-(2′-Allyloxyphenyl)prop-2-en-1-ol (8a)
(0.050 g, 0.260 mmol) was dissolved in dichloromethane (15 mL) and
cooled to 0 °C under argon with stirring. Trichloroacetonitrile (0.040
mL, 0.400 mmol) was added to the solution, followed by 1,8-
diazabicyclo[5.4.0]undec-7-ene (0.020 mL, 0.130 mmol), and the
reaction was allowed to return to room temperature over 1 h. The
reaction mixture was ﬁltered through a short pad of alumina (neutral,
Brockman V) with diethyl ether (150 mL) and concentrated in vacuo
to yield the crude allylic trichloroacetimidate 9a as a yellow oil which
was used without further puriﬁcation. Allylic trichloroacetimidate 9a
was transferred to a dry Schlenk tube containing a stirrer bar and
potassium carbonate (15 mg, 3 mg/mL) to which p-xylene (5 mL) was
then added. The tube was purged with argon, sealed, and heated to
140 °C for 18 h. The reaction was allowed to cool to room
temperature, and Grubbs second-generation catalyst (0.110 g, 0.013
mmol) was added. The reaction mixture was heated to 50 °C for 20 h.
The reaction mixture was concentrated in vacuo and puriﬁed by
column chromatography (elution with 10% diethyl ether in petroleum
ether) that gave 5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihy-
dro-1-benzoxepine (11a) (0.055 g, 68%) as a white solid. Mp 96−98
°C; IR (neat) 3260, 3055, 1686, 1539, 1269, 1227, 1072, 822, 725
cm−1; 1H NMR (400 MHz, CDCl3) δ 4.44 (dddd, J = 17.6, 2.6, 2.0,
1.0 Hz, 1H), 4.82 (dddd, J = 17.6, 3.5, 2.0, 1.0 Hz, 1H), 5.41 (br t, J =
7.7 Hz, 1H), 5.70 (ddd, J = 11.5, 3.5, 2.6 Hz, 1H), 6.11 (ddt, J = 11.5,
7.7, 2.0 Hz, 1H), 7.10−7.16 (m, 2H), 7.27−7.34 (m, 2H), 7.63 (br d, J
= 7.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 51.5 (CH), 71.1
(CH2), 92.7 (C), 122.1 (CH), 125.1 (CH), 126.0 (CH), 128.3 (CH),
130.1 (CH), 131.6 (CH), 134.9 (C), 157.3 (C), 160.6 (C); MS (CI)
m/z 307 (MH+, 100), 272 (37), 257 (62), 197 (13), 157 (28), 145
(64), 113 (35), 71 (53); HRMS (CI) calcd for C12H11
35Cl2
37ClNO2
(MH+), 307.9827, found 307.9830.
6-Methoxy-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-
dihydro-1-benzoxepine (11b). The reaction was carried out as
described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-6′-
methoxyphenyl)prop-2-en-1-ol (8b) (0.049 g, 0.22 mmol). This
gave 6-methoxy-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihy-
dro-1-benzoxepine (11b) (0.046 g, 61%) as colorless oil. IR (neat)
3412, 2938, 1710, 1602, 1471, 1278, 1088, 818 cm−1; 1H NMR (500
MHz, CDCl3) δ 3.85 (s, 3H), 4.36−4.43 (m, 1H), 4.83 (ddd, J = 17.6,
3.6, 2.1 Hz, 1H), 5.65 (ddd, J = 10.7, 3.6, 1.9 Hz, 1H), 6.00 (t, J = 8.1
Hz, 1H), 6.17 (dddd, J = 10.7, 8.1, 2.6, 2.1 Hz, 1H), 6.73 (dd, J = 8.2,
0.7 Hz, 1H), 6.75 (dd, J = 8.2, 0.7 Hz, 1H), 7.24 (t, J = 8.2 Hz, 1H),
7.78 (d, J = 8.1 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 43.0 (CH),
56.3 (CH3), 71.3 (CH2), 93.0 (C), 108.2 (CH), 114.3 (CH), 123.9
(C), 126.7 (CH), 130.1 (CH), 131.3 (CH), 156.3 (C), 158.8 (C),
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160.6 (C); MS (ESI) m/z 358 (MNa+, 100); HRMS (ESI) calcd for
C13H12
35Cl3NNaO3 (MNa
+), 357.9775, found 357.9766.
7-Methoxy-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-
dihydro-1-benzoxepine (11c). The reaction was carried out as
described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-5′-
methoxyphenyl)prop-2-en-1-ol (8c) (0.064 g, 0.29 mmol). This gave
7-methoxy-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihydro-1-
benzoxepine (11c) (0.075 g, 76%) as yellow oil. IR (neat) 3329, 2938,
1702, 1490, 1265, 1205, 1034, 818 cm−1; 1H NMR (500 MHz,
CDCl3) δ 3.78 (s, 3H), 4.34−4.44 (m, 1H), 4.76 (ddd, J = 17.7, 3.3,
2.3 Hz, 1H), 5.34 (t, J = 8.0 Hz, 1H), 5.68 (ddd, J = 11.6, 3.3, 2.0 Hz,
1H), 6.09 (ddt, J = 11.6, 8.0, 2.3 Hz, 1H), 6.79 (dd, J = 8.3, 3.0 Hz,
1H), 6.81 (d, J = 3.0 Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 8.0
Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 51.6 (CH), 55.8 (CH3),
71.5 (CH2), 92.8 (C), 113.6 (CH), 114.7 (CH), 122.8 (CH), 126.0
(CH), 131.9 (CH), 135.8 (C), 150.9 (C), 156.5 (C), 160.8 (C); MS
(ESI) m/z 358 (MNa+, 100); HRMS (ESI) calcd for
C13H12
35Cl3NNaO3 (MNa
+), 357.9775, found 357.9769.
8-Methoxy-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-
dihydro-1-benzoxepine (11d). The reaction was carried out as
described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-4′-
methoxyphenyl)prop-2-en-1-ol (8d) (0.048 g, 0.22 mmol). This
gave 8-methoxy-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihy-
dro-1-benzoxepine (11d) (0.051 g, 69%) as colorless oil. IR (neat)
3419, 2935, 1706, 1613, 1496, 1156, 1122, 1032, 819 cm−1; 1H NMR
(500 MHz, CDCl3) δ 3.79 (s, 3H), 4.43 (br d, J = 17.6 Hz, 1H), 4.79
(ddd, J = 17.6, 3.6, 1.9 Hz, 1H), 5.33 (t, J = 8.3 Hz, 1H), 5.69 (ddd, J =
11.5, 3.6, 1.9 Hz, 1H), 6.09 (ddt, J = 11.5, 8.3, 1.9 Hz, 1H), 6.64 (dd, J
= 8.3, 2.6 Hz, 1H), 6.68 (d, J = 2.6 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H),
7.53 (d, J = 8.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 51.3 (CH),
55.6 (CH3), 71.2 (CH2), 92.8 (C), 108.3 (CH), 110.0 (CH), 126.3
(CH), 127.1 (C), 129.3 (CH), 131.5 (CH), 158.4 (C), 160.7 (C),
161.1 (C); MS (ESI) m/z 358 (MNa+, 100); HRMS (ESI) calcd for
C13H12
35Cl3NNaO3 (MNa
+), 357.9775, found 357.9781.
7-Methyl-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-di-
hydro-1-benzoxepine (11e). The reaction was carried out as
described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxyphenyl-
5′-methyl)prop-2-en-1-ol (8e) (0.150 g, 0.730 mmol). This gave 7-
methyl-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihydro-1-ben-
zoxepine (11e) (0.173 g, 73%) as a white solid. Mp 146−148 °C; IR
(neat) 3306, 1713, 1530, 1494, 1234, 1064, 825 cm−1; 1H NMR (500
MHz, CDCl3) δ 2.31 (s, 3H), 4.40 (br dt, J = 17.6, 2.1 Hz, 1H), 4.79
(ddd, J = 17.6, 3.5, 2.1 Hz, 1H), 5.33 (t, J = 8.1 Hz, 1H), 5.69 (ddd, J =
11.5, 3.5, 2.1 Hz, 1H), 6.11 (ddt, J = 11.5, 8.1, 2.1 Hz, 1H), 7.01 (d, J =
8.3 Hz, 1H), 7.08−7.12 (m, 2H), 7.65 (d, J = 8.1 Hz, 1H); 13C NMR
(126 MHz, CDCl3) δ 20.8 (CH3), 51.5 (CH), 71.2 (CH2), 92.7 (C),
121.7 (CH), 126.0 (CH), 128.9 (CH), 130.4 (CH), 131.7 (CH),
134.5 (C), 134.7 (C), 155.0 (C), 160.6 (C); MS (ESI) m/z 342
(MNa+, 100); HRMS (ESI) calcd for C13H12
35Cl3NNaO2 (MNa
+),
341.9826, found 341.9811.
7-Nitro-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihy-
dro-1-benzoxepine (11f). The reaction was carried out as described
for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-
dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-5′-
nitrophenyl)prop-2-en-1-ol (8f) (0.060 g, 0.26 mmol), except that
the Overman rearrangement was heated at 140 °C for 60 h and 7.5
mol % of Grubbs second-generation catalyst was used for the RCM
step. This gave 7-nitro-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-
dihydro-1-benzoxepine (11f) (0.063 g, 71%) as a white solid. Mp 170
°C (decomposition); IR (neat) 3337, 2841, 1694, 1522, 1491, 1344,
1236, 1047, 820 cm−1; 1H NMR (500 MHz, CDCl3) δ 4.50−4.59 (m,
1H), 4.85−4.92 (m, 1H), 5.57 (t, J = 7.5 Hz, 1H), 5.78 (ddd, J = 11.6,
3.0, 2.4 Hz, 1H), 6.09 (ddt, J = 11.6, 7.5, 2.4 Hz, 1H), 7.24−7.30 (m,
1H), 7.45 (br d, J = 7.5 Hz, 1H), 8.21 (dd, J = 9.5, 4.5 Hz, 1H), 8.22
(d, J = 4.5 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 51.0 (CH), 71.4
(CH2), 92.4 (C), 123.4 (CH), 123.8 (CH), 125.4 (CH), 125.9 (CH),
131.5 (CH), 136.4 (C), 144.6 (C), 161.1 (C), 162.4 (C); MS (ESI)
m/z 373 (MNa+, 100); HRMS (ESI) calcd for C12H9
35Cl3N2NaO4
(MNa+), 372.9520, found 372.9514.
7-Chloro-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-di-
hydro-1-benzoxepine (11g). The reaction was carried out as
described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-5′-
chlorophenyl)prop-2-en-1-ol (8g) (0.055 g, 0.25 mmol), except that
the Overman rearrangement was heated at 140 °C for 60 h. This gave
7-chloro-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihydro-1-
benzoxepine (11g) (0.058 g, 69%) as white solid. Mp 136−138 °C; IR
(neat) 3260, 2943, 1708, 1687, 1539, 1480, 1267, 1066, 825 cm−1; 1H
NMR (500 MHz, CDCl3) δ 4.42 (br d, J = 17.7 Hz, 1H), 4.75−4.85
(m, 1H), 5.36 (t, J = 7.9 Hz, 1H), 5.72 (ddd, J = 11.7, 3.4, 2.0 Hz, 1H),
6.07 (ddt, J = 11.7, 7.9, 2.3 Hz, 1H), 7.07 (d, J = 8.3 Hz, 1H), 7.23−
7.30 (m, 2H), 7.55 (d, J = 7.9 Hz, 1H); 13C NMR (126 MHz, CDCl3)
δ 51.0 (CH), 71.3 (CH2), 92.6 (C), 123.6 (CH), 125.6 (CH), 128.3
(CH), 130.0 (CH), 130.2 (C), 131.8 (CH), 136.6 (C), 155.9 (C),
160.8 (C); MS (ESI) m/z 362 (MNa+, 100); HRMS (ESI) calcd for
C12H9
35Cl4NNaO2 (MNa
+), 361.9280, found 361.9268.
7-Bromo-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-di-
hydro-1-benzoxepine (11h). The reaction was carried out as
described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-5′-
bromophenyl)prop-2-en-1-ol (8h) (0.10 g, 0.29 mmol), except that
the Overman rearrangement was heated at 140 °C for 48 h. This gave
7-bromo-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihydro-1-
benzoxepine (11h) (0.11 g, 79%) as white solid. Mp 147−149 °C; IR
(neat) 3267, 2890, 1707, 1687, 1535, 1478, 1267, 1067, 822 cm−1; 1H
NMR (500 MHz, CDCl3) δ 4.37−4.46 (m, 1H), 4.81 (ddd, J = 17.7,
3.3, 2.3 Hz, 1H), 5.36 (t, J = 8.2 Hz, 1H), 5.71 (ddd, J = 11.7, 3.3, 2.0
Hz, 1H), 6.07 (ddt, J = 11.7, 8.2, 2.3 Hz, 1H), 7.01 (d, J = 8.2 Hz, 1H),
7.42 (dd, J = 8.2, 2.5 Hz, 1H), 7.43 (d, J = 2.5 Hz, 1H), 7.54 (d, J = 8.2
Hz, 1H); δC (126 MHz, CDCl3) δ 51.0 (CH), 71.3 (CH2), 92.6 (C),
117.8 (C), 124.0 (CH), 125.6 (CH), 131.2 (CH), 131.8 (CH), 133.0
(CH), 137.0 (C), 156.4 (C), 160.8 (C); MS (ESI) m/z 406 (MNa+,
100); HRMS (ESI) calcd for C12H9
79Br35Cl3NNaO2 (MNa
+),
405.8774, found 405.8764.
8-Chloro-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-di-
hydro-1-benzoxepine (11i). The reaction was carried out as
described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-4′-
chlorophenyl)prop-2-en-1-ol (8i) (0.130 g, 0.580 mmol), except that
the Overman rearrangement was heated at 140 °C for 24 h. This gave
8-chloro-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihydro-1-
benzoxepine (11i) (0.141 g, 71%) as a yellow oil. IR (neat) 3416,
2960, 1700, 1598, 1490, 1480, 1271, 1225, 1077, 906, 836, 821, 731
cm−1; 1H NMR (400 MHz, CDCl3) δ 4.45 (br dt, J = 17.6, 2.1 Hz,
1H), 4.82 (ddd, J = 17.6, 3.4, 2.1 Hz, 1H), 5.38 (t, J = 7.8 Hz, 1H),
5.72 (ddd, J = 11.5, 3.4, 2.1 Hz, 1H), 6.07 (ddt, J = 11.5, 7.8, 2.1 Hz,
1H), 7.11 (dd, J = 8.1, 2.0 Hz, 1H), 7.14 (d, J = 2.0 Hz, 1H), 7.23 (d, J
= 8.1 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H); 13C NMR (101 MHz, CDCl3)
δ 51.0 (CH), 71.2 (CH2), 92.5 (C), 122.8 (CH), 125.2 (CH), 125.6
(CH), 129.3 (CH), 131.6 (CH), 133.4 (C), 134.9 (C), 157.8 (C),
160.7 (C); MS (ESI) m/z 362 (MNa+, 100); HRMS (ESI) calcd for
C12H9
35Cl4NNaO2 (MNa
+), 361.9280, found 361.9264.
7,8-Diﬂuoro-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-
dihydro-1-benzoxepine (11j). The reaction was carried out as
described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-4′,5′-
diﬂuorophenyl)prop-2-en-1-ol (8j) (0.040 g, 0.180 mmol), except that
the Overman rearrangement was heated at 140 °C for 24 h. This gave
7,8-diﬂuoro-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihydro-1-
benzoxepine (11j) (0.042 g, 68%) as a white solid. Mp 106−108 °C;
IR (neat) 3264, 2925, 1711, 1691, 1620, 1542, 1500, 1267, 1161, 888
cm−1; 1H NMR (500 MHz, CDCl3) δ 4.44 (ddd, J = 17.6, 3.5, 2.1 Hz,
1H), 4.79 (ddd, J = 17.6, 2.8, 2.1 Hz, 1H), 5.34 (t, J = 7.8 Hz, 1H),
5.73 (ddd, J = 11.5, 3.5, 2.8 Hz, 1H), 6.05 (ddt, J = 11.5, 7.8, 2.1 Hz,
1H), 6.97 (dd, 3JHF = 10.2,
4JHF = 6.8 Hz, 1H), 7.14 (dd,
3JHF = 10.2,
4JHF = 8.7 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H);
13C NMR (101 MHz,
CDCl3) δ 50.7 (CH), 71.2 (CH2), 92.4 (C), 111.8 (d,
2JCF = 18.3 Hz,
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CH), 116.8 (dd, 2JCF = 19.0,
3JCF = 1.4 Hz, CH), 125.4 (CH), 131.3
(dd, 3JCF = 5.1,
4JCF = 3.6 Hz, C), 131.6 (CH), 147.0 (dd,
1JCF = 247.0,
2JCF = 12.5 Hz, C), 150.1 (dd,
1JCF = 251.6,
2JCF = 13.7 Hz, C), 153.1
(dd, 3JCF = 8.3,
4JCF = 3.1 Hz, C), 160.8 (C); MS (CI) m/z 342 (MH
+,
100), 308 (49), 274 (8), 238 (18), 181 (96), 81 (20), 69 (28); HRMS
(CI) calcd for C12H9
35Cl3F2NO2 (MH
+), 341.9667, found 341.9665.
9-Methoxy-7-nitro-5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11k). The reaction was carried
out as described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbo-
nylamino)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-
3′-methoxy-5′-nitrophenyl)prop-2-en-1-ol (8k) (0.215 g, 0.810
mmol), except that the Overman rearrangement was heated at 140
°C for 48 h. This gave 9-methoxy-7-nitro-5-(2′,2′,2′-trichloromethyl-
carbonylamino)-2,5-dihydro-1-benzoxepine (11k) (0.162 g, 52%) as a
white solid. Mp 180−182 °C; IR (neat) 3327, 2943, 1702, 1526, 1342,
1056, 909, 822 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.99 (s, 3H),
4.52 (ddd, J = 17.8, 3.5, 2.1 Hz, 1H), 4.89 (ddd, J = 17.8, 2.8, 2.1 Hz,
1H), 5.54 (t, J = 8.1 Hz, 1H), 5.76 (ddd, J = 11.6, 3.5, 2.8 Hz, 1H),
6.09 (ddt, J = 11.6, 8.1, 2.1 Hz, 1H), 7.54 (br d, J = 8.1 Hz, 1H), 7.83
(d, J = 2.5 Hz, 1H), 7.86 (d, J = 2.5 Hz, 1H); 13C NMR (126 MHz,
CDCl3) δ 50.8 (CH), 56.6 (CH3), 70.4 (CH2), 92.3 (C), 108.1 (CH),
115.3 (CH), 125.4 (CH), 131.4 (CH), 137.3 (C), 144.6 (C), 150.7
(C), 152.9 (C), 160.9 (C); MS (ESI) m/z 403 (MNa+, 100); HRMS
(ESI) calcd for C13H11
35Cl3N2NaO5 (MNa
+), 402.9626, found
402.9609.
5-(2′,2′,2′-Trichloromethylcarbonylamino)-2,5-dihydro-1-
naphtho[2,1-b]oxepine (11l). The reaction was carried out as
described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2 ′ -
allyloxynaphthyl)prop-2-en-1-ol (8l) (0.205 g, 0.850 mmol). This
gave 5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihydro-1-
naphtho[2,1-b]oxepine (11l) (0.140 g. 46%) as a white solid. Mp
136−138 °C; IR (neat) 3406, 2940, 1701, 1492, 1220, 1045, 818
cm−1; 1H NMR (400 MHz, CDCl3) δ 4.48 (br dt, J = 17.6, 2.1 Hz,
1H), 4.93 (ddd, J = 17.6, 3.5, 2.1 Hz, 1H), 5.76 (ddd, J = 11.0, 3.5, 2.1
Hz, 1H), 6.25−6.30 (m, 1H), 6.32 (br t, J = 8.4 Hz, 1H), 7.32 (d, J =
8.4 Hz, 1H), 7.47 (ddd, J = 8.5, 8.4, 1.3 Hz, 1H), 7.60 (ddd, J = 8.5,
8.4, 1.3 Hz, 1H), 7.83−7.87 (m, 2H), 7.99 (d, J = 8.4 Hz, 1H), 8.29
(br d, J = 8.4 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 44.9 (CH),
70.5 (CH2), 92.7 (C), 121.5 (CH), 122.9 (CH), 125.3 (CH), 126.0
(CH), 127.4 (CH), 128.6 (CH), 129.7 (C), 130.6 (C), 130.8 (CH),
131.4 (C), 131.8 (CH), 155.4 (C), 160.8 (C); MS (ESI) m/z 378
(MNa+, 100); HRMS (ESI) calcd for C16H12
35Cl3NNaO2 (MNa
+),
377.9826, found 377.9808.
Methyl 4-(4′-ﬂuorophenyl)-2-hydroxybenzoate (14).37 4-
Fluorophenylboronic acid (12) (0.378 g, 2.70 mmol), cesium
carbonate (1.47 g, 4.50 mmol), and [1,1′-bis(diphenylphosphino)-
ferrocene]palladium(II) dichloride (0.0735 g, 0.0899 mmol) were
added to a degassed solution of methyl 2-hydroxy-4-iodobenzoate
(13) (0.500 g, 1.80 mmol) in 1,4-dioxane (17 mL) and water (1 mL).
The solution was heated to 80 °C for 18 h, cooled to room
temperature, and concentrated in vacuo. The reaction mixture was
puriﬁed by column chromatography (elution with 20% diethyl ether in
petroleum ether) to yield methyl 4-(4′-ﬂuorophenyl)-2-hydroxyben-
zoate (14) (0.442 g, 100%) as a white solid. Mp 110−112 °C;
Spectroscopic data were in accordance with literature values.37 1H
NMR (500 MHz, CDCl3) δ 3.97 (s, 3H), 7.06 (dd, J = 8.4, 1.0 Hz,
1H), 7.10−7.17 (m, 3H), 7.57 (dd, J = 8.4, 3JHF = 5.4 Hz, 2H), 7.87
(d, J = 8.4 Hz, 1H), 10.82 (br s, 1H); 13C NMR (126 MHz, CDCl3) δ
52.4 (CH3), 111.3 (C), 115.7 (CH), 116.0 (2 × CH, d,
2JCF = 21.6
Hz), 118.1 (CH), 129.0 (2 × CH, d, 3JCF = 8.2 Hz), 130.5 (CH),
135.9 (C, d, 4JCF = 3.2 Hz), 147.6 (C), 162.0 (C), 163.2 (C, d,
1JCF =
248.3 Hz), 170.6 (C); MS (EI) m/z 246 (M+, 82), 214 (100), 186
(45), 157 (30), 133 (10), 93 (9), 84 (30), 49 (34).
4-(4′-Fluorophenyl)-2-hydroxybenzyl alcohol. Lithium alumi-
num hydride (0.663 g, 17.5 mmol) was added to a solution of methyl
4-(4′-ﬂuorophenyl)-2-hydroxybenzoate (14) (1.72 g, 6.98 mmol) in
tetrahydrofuran (70 mL) and stirred at room temperature for 18 h.
The reaction mixture was cooled to 0 °C and quenched by addition of
2 M hydrochloric acid (70 mL). The solution was extracted with
dichloromethane (2 × 70 mL), washed with water (2 × 50 mL), and
brine (70 mL), dried (MgSO4), ﬁltered, and concentrated in vacuo to
yield 4-(4′-ﬂuorophenyl)-2-hydroxybenzyl alcohol (1.52 g, 100%) as a
white solid. Mp 105−107 °C; IR (neat) 3441, 3395, 2918, 1491, 1241,
1184, 988, 822 cm−1; 1H NMR (400 MHz, CDCl3) δ 2.23 (br s, 1H),
4.92 (s, 2H), 7.03 (dd, J 7.9, 1.6 Hz, 1H), 7.06−7.16 (m, 4H), 7.40 (br
s, 1H), 7.48−7.56 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 64.6
(CH2), 115.3 (CH), 115.8 (2 × CH, d,
2JCF = 21.5 Hz), 118.8 (CH),
123.6 (C), 128.4 (CH), 128.7 (2 × CH, d, 3JCF = 8.1 Hz), 136.7 (C),
141.9 (C), 156.6 (C), 162.7 (C, d, 1JCF = 246.4 Hz); MS (EI) m/z 218
(M+, 63), 200 (68), 172 (100), 133 (17), 120 (80), 85 (7); HRMS
(EI) calcd for C13H11FO2 (M
+), 218.0743, found 218.0742.
2-Allyloxy-4-(4′-ﬂuorophenyl)benzyl alcohol (15). Allyl bro-
mide (0.79 mL, 9.2 mmol) was added to a solution of 4-(4′-
ﬂuorophenyl)-2-hydroxybenzyl alcohol (1.0 g, 4.6 mmol), potassium
carbonate (0.95 g, 6.9 mmol), and sodium iodide (0.041 g, 0.28
mmol) in N,N′-dimethylformamide (31 mL) and stirred at room
temperature for 24 h. The solution was diluted with diethyl ether (60
mL), washed with 5% lithium chloride solution (3 × 50 mL), and
brine (50 mL), dried (MgSO4), ﬁltered, and concentrated in vacuo.
Puriﬁcation by column chromatography (elution with 20% diethyl
ether in petroleum ether) gave 2-allyloxy-4-(4′-ﬂuorophenyl)benzyl
alcohol (15) (0.95 g, 80%) as a white solid. Mp 54−56 °C; IR (neat)
3354, 2853, 1610, 1496, 1221, 1001, 819 cm−1; 1H NMR (500 MHz,
CDCl3) δ 2.38 (t, J 5.6 Hz, 1H), 4.66 (dt, J = 5.2, 1.5 Hz, 2H), 4.75 (d,
J = 5.6 Hz, 2H), 5.32 (ddt, J = 10.5, 2.9, 1.5 Hz, 1H), 5.44 (ddt, J =
17.3, 2.9, 1.5 Hz, 1H), 6.09 (ddt, J = 17.3, 10.5, 5.2 Hz, 1H), 7.02 (d, J
= 1.5 Hz, 1H), 7.06−7.15 (m, 3H), 7.34 (d, J = 7.7 Hz, 1H), 7.44−
7.65 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 61.9 (CH2), 69.0
(CH2), 110.6 (CH), 115.8 (2 × CH, d,
2JCF = 21.4 Hz), 118.0 (CH2),
119.7 (CH), 128.6 (C), 128.8 (2 × CH, d, 3JCF = 8.0 Hz), 129.3 (CH),
133.1 (CH), 137.3 (C, d, 4JCF = 3.2 Hz), 141.4 (C), 156.9 (C), 162.7
(C, d, 1JCF = 246.6 Hz); MS (EI) m/z 258 (M
+, 100), 228 (17), 215
(27), 200 (57), 172 (70), 133 (17), 120 (6); HRMS (EI) calcd for
C16H15FO2 (M
+), 258.1056, found 258.1054.
Ethyl (2E)-3-(2′-Allyloxy-4′-[4‴-ﬂuorophenyl]phenyl)prop-2-
enoate (16). Dimethyl sulfoxide (0.64 mL, 9.0 mmol) was added to a
stirred solution of oxalyl chloride (0.40 mL, 4.5 mmol) in
dichloromethane (15 mL) at −78 °C. The reaction mixture was
stirred for 0.3 h, then 2-allyloxy-4-(4′-ﬂuorophenyl)benzyl alcohol
(15) (0.78 g, 3.0 mmol) in dichloromethane (15 mL) was slowly
added. The mixture was stirred for a further 0.3 h, then triethylamine
(2.1 mL, 15 mmol) was added. This reaction mixture was stirred for
0.5 h at −78 °C and then allowed to warm to room temperature and
stirred for a further 2 h. Meanwhile, a solution of lithium bromide (1.0
g, 12 mmol), triethyl phosphonoacetate (2.0 mL, 10 mmol), and 1,8-
diazabicyclo[5.4.0]undec-7-ene (1.5 mL, 10 mmol) in acetonitrile (30
mL) was prepared and stirred for 1.0 h. The Swern solution was
concentrated in vacuo, and the Horner−Wadsworth−Emmons
solution was added. The reaction mixture was stirred at room
temperature for 18 h. The reaction mixture was quenched by the
addition of a saturated solution of ammonium chloride (20 mL) and
concentrated to give an orange residue, which was then extracted with
diethyl ether (2 × 30 mL). The organic layers were combined, washed
with water (50 mL), and brine (50 mL), then dried (MgSO4) and
concentrated to give a yellow oil. Puriﬁcation by column
chromatography (elution with 5% diethyl ether in petroleum ether)
gave ethyl (2E)-3-(2′-allyloxy-4′-[4‴-ﬂuorophenyl]phenyl)prop-2-
enoate (16) (0.83 g, 84%) as a white solid. Mp 75−76 °C; IR
(neat) 2981, 1702, 1628, 1604, 1492, 1307, 1217, 1158, 986, 811
cm−1; 1H NMR (500 MHz, CDCl3) δ 1.35 (t, J = 7.1 Hz, 3H), 4.27 (q,
J = 7.1 Hz, 2H), 4.69 (d, J = 5.2 Hz, 2H), 5.34 (dd, J = 10.5, 1.4 Hz,
1H), 5.46 (dd, J = 17.2, 1.4 Hz, 1H), 6.11 (ddt, J = 17.2, 10.5, 5.2 Hz,
1H), 6.56 (d, J = 16.2 Hz, 1H), 7.04 (d, J = 1.3 Hz, 1H), 7.09−7.18
(m, 3H), 7.48−7.55 (m, 2H), 7.56 (d, J = 8.0 Hz, 1H), 8.06 (d, J =
16.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.5 (CH3), 60.4
(CH2), 69.4 (CH2), 111.2 (CH), 115.9 (2 × CH, d,
2JCF = 21.5 Hz),
118.0 (CH2), 118.8 (CH), 119.7 (CH), 122.9 (C), 128.8 (2 × CH, d,
3JCF = 8.1 Hz), 129.3 (CH), 132.9 (CH), 136.6 (C, d,
4JCF = 3.2 Hz),
139.5 (CH), 143.4 (C), 157.7 (C), 162.9 (C, d, 1JCF = 247.6 Hz),
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167.6 (C); MS (EI) m/z 326 (M+, 100), 281 (23), 252 (20), 238 (37),
225 (17), 212 (83), 183 (64), 165 (9), 157 (7), 133 (6), 113 (5);
HRMS (EI) calcd for C20H19FO3 (M
+), 326.1318, found 326.1316.
(2E)-3-(2′-Allyloxy-4′-[4‴-ﬂuorophenyl]phenyl)prop-2-en-1-
ol (17). The reaction was carried out as described for the synthesis of
(2E)-3-(2′-allyloxyphenyl)prop-2-en-1-ol (8a) using ethyl (2E)-3-(2′-
allyloxy-4′-[4‴-ﬂuorophenyl]phenyl)prop-2-enoate (16) (0.79 g, 2.4
mmol). This gave (2E)-3-(2′-allyloxy-4′-[4‴-ﬂuorophenyl]phenyl)-
prop-2-en-1-ol (17) (0.63 g, 92%) as a white solid. Mp 84−86 °C; IR
(neat) 3335, 2867, 1602, 1519, 1493, 1392, 1220, 1014, 972, 827
cm−1; 1H NMR (400 MHz, CDCl3) δ 1.50 (br s, 1H), 4.36 (dd, J =
5.9, 1.1 Hz, 2H), 4.65 (dt, J = 5.2, 1.5 Hz, 2H), 5.32 (dq, J = 10.5, 1.5
Hz, 1H), 5.45 (dq, J = 17.3, 1.5 Hz, 1H), 6.11 (ddt, J = 17.3, 10.5, 5.2
Hz, 1H), 6.45 (dt, J = 16.1, 5.9 Hz, 1H), 6.99 (dt, J = 16.1, 1.1 Hz,
1H), 7.02 (d, J = 1.7 Hz, 1H), 7.08−7.16 (m, 3H), 7.47−7.57 (m,
3H); 13C NMR (101 MHz, CDCl3) δ 64.4 (CH2), 69.5 (CH2), 111.2
(CH), 115.8 (2 × CH, d, 2JCF = 21.4 Hz), 117.8 (CH2), 119.8 (CH),
125.2 (C), 125.9 (CH), 127.5 (CH), 128.6 (2 × CH, d, 3JCF = 8.0 Hz),
129.5 (CH), 133.4 (CH), 137.1 (C, d, 4JCF = 3.2 Hz), 140.9 (C), 156.2
(C), 162.7 (C, d, 1JCF = 246.8 Hz); MS (EI) m/z 284 (M
+, 100), 243
(49), 225 (47), 215 (42), 196 (26), 183 (38), 165 (19), 133 (11), 107
(6), 55 (6); HRMS (EI) calcd for C18H17FO2 (M
+), 284.1213, found
284.1214.
8-(4″-Fluorophenyl)-5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (18). The reaction was carried out
as described for the synthesis of 5-(2′,2′,2′-trichloromethylcarbonyla-
mino)-2,5-dihydro-1-benzoxepine (11a) using (2E)-3-(2′-allyloxy-4′-
[4‴-ﬂuorophenyl]phenyl)prop-2-en-1-ol (17) (0.200 g, 0.700 mmol).
This gave 8-(4″-ﬂuorophenyl)-5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,5-dihydro-1-benzoxepine (18) (0.277 g, 98%) as a white solid.
Mp 115−117 °C; IR (neat) 3416, 2932, 1703, 1489, 1223, 907, 816,
729 cm−1; 1H NMR (500 MHz, CDCl3) δ 4.50 (br d, J = 17.7 Hz,
1H), 4.86 (ddd, J = 17.7, 3.3, 2.2 Hz, 1H), 5.45 (t, J = 8.2 Hz, 1H),
5.74 (ddd, J = 11.6, 3.3, 1.9 Hz, 1H), 6.13 (ddt, J = 11.6, 8.2, 2.2 Hz,
1H), 7.09−7.15 (m, 2H), 7.30 (dd, J = 7.8, 1.5 Hz, 1H), 7.32 (d, J =
1.5 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.50−7.56 (m, 2H), 7.63 (d, J =
8.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 51.4 (CH), 71.3 (CH2),
92.8 (C), 115.9 (2 × CH, d, 2JCF = 21.5 Hz), 120.8 (CH), 123.6 (CH),
126.1 (CH), 128.7 (2 × CH, d, 3JCF = 8.1 Hz), 128.9 (CH), 131.8
(CH), 133.7 (C), 136.1 (C, d, 4JCF = 3.2 Hz), 142.5 (C), 157.7 (C),
160.8 (C), 162.8 (C, d, 1JCF = 247.2 Hz); MS (EI) m/z 399 (M
+, 12),
364 (100), 328 (59), 294 (12), 252 (20), 238 (67), 225 (18), 209
(20), 196 (23), 183 (21), 157 (8), 133 (7), 120 (6); HRMS (EI) calcd
for C18H13
35Cl3FNO2 (M
+), 398.9996, found 398.9980.
8-(4″-Fluorophenyl)-5-(2′,2′,2′-trichloromethylcarbonylami-
no)-2,3,4,5-tetrahydro-1-benzoxepine (19). p-Toluenesulfonyl
hydrazide (0.030 g, 0.16 mmol) and potassium acetate (0.016 g,
0.16 mmol) were added to a stirred solution of 8-(4″-ﬂuorophenyl)-5-
(2′,2′,2′-trichloromethylcarbonylamino)-2,5-dihydro-1-benzoxepine
(18) (0.033 g, 0.082 mmol) in butan-1-ol (0.8 mL) at 50 °C. The
reaction mixture was heated to 100 °C, and four additional portions of
p-toluenesulfonyl hydrazide (0.030 g, 0.16 mmol) and potassium
acetate (0.016 g, 0.16 mmol) were added at 1 h intervals. After 5 h, the
reaction mixture was cooled to room temperature and diluted with
diethyl ether (10 mL), washed with 1 M sodium hydroxide (10 mL),
water (10 mL), and brine (10 mL), then dried (MgSO4), ﬁltered, and
concentrated in vacuo. Puriﬁcation by column chromatography
(elution with 10% diethyl ether in petroleum ether) gave 8-(4″-
ﬂuorophenyl)-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,3,4,5-tetra-
hydro-1-benzoxepine (19) (0.027 g, 81%) as a white solid. Mp 128−
130 °C; IR (neat) 3415, 2941, 1712, 1491, 1226, 817 cm−1; 1H NMR
(400 MHz, CDCl3) δ 1.77−1.95 (m, 2H), 2.22−2.42 (m, 2H), 3.79
(td, J = 11.9, 1.7 Hz, 1H), 4.43−4.50 (m, 1H), 5.18 (ddd, J = 8.1, 6.1,
1.7 Hz, 1H), 7.09−7.17 (m, 2H), 7.23−7.29 (m, 2H), 7.33 (d, J = 8.5
Hz, 1H), 7.45−7.56 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 26.6
(CH2), 29.8 (CH2), 54.9 (CH), 74.2 (CH2), 92.9 (C), 115.9 (2 × CH,
d, 2JCF = 21.5 Hz), 121.1 (CH), 123.1 (CH), 128.7 (2 × CH, d,
3JCF =
8.1 Hz), 130.2 (CH), 132.3 (C), 136.1 (C, d, 4JCF = 3.3 Hz), 142.3
(C), 160.0 (C), 161.0 (C), 162.9 (C, d, 1JCF = 247.2 Hz); MS (EI) m/
z 401 (M+, 11), 366 (100), 330 (27), 296 (15), 283 (12), 241 (38),
212 (24), 183 (22), 170 (16), 84 (61); HRMS (EI) calcd for
C18H15
35Cl3FNO2 (M
+), 401.0152, found 401.0150.
8-Chloro-5-(2′,2′-dichloromethylcarbonylamino)-2,3,4,5-tet-
rahydro-1-benzoxepine (21). 10% Palladium on charcoal (0.03 g)
was added to a solution of 8-chloro-5-(2′,2′,2′-trichloromethylcarbo-
nylamino)-2,5-dihydro-1-benzoxepine (11i) (0.120 g, 0.350 mmol) in
ethyl acetate (7 mL). The mixture was stirred under an atmosphere of
hydrogen at room temperature for 1.5 h. The reaction mixture was
ﬁltered through a short pad of Celite with diethyl ether (100 mL),
concentrated in vacuo, and puriﬁed by column chromatography
(elution with 10% diethyl ether in petroleum ether). This gave 8-
chloro-5-(2′,2′-dichloromethylcarbonylamino)-2,3,4,5-tetrahydroben-
zoxepine (21) (0.102 g, 94%) as a white solid. Mp 106−108 °C; IR
(neat) 3263, 2936, 1670, 1561, 1479, 1284, 1223, 1213, 1080, 1042,
983, 952, 808 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.73−1.93 (m,
2H), 2.18−2.30 (m, 2H), 3.76 (td, J = 12.0, 2.0 Hz, 1H), 4.38 (dt, J =
12.0, 1.1 Hz, 1H), 5.16 (ddd, J = 7.8, 6.2, 1.6 Hz, 1H), 5.94 (s, 1H),
7.05 (dd, J = 8.0, 2.1 Hz, 1H), 7.07 (d, J = 2.1 Hz, 1H), 7.17 (d, J = 8.0
Hz, 1H), 7.20 (d, J = 7.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ
26.4 (CH2), 29.8 (CH2), 53.2 (CH), 66.5 (CH), 74.1 (CH2), 122.9
(CH), 124.6 (CH), 130.3 (CH), 132.3 (C), 134.5 (C), 160.1 (C),
163.0 (C); MS (ESI) m/z 330 (MNa+, 100); HRMS (ESI) calcd for
C12H12
35Cl3NNaO2 (MNa
+), 329.9826, found 329.9812.
5-N,N′-Bis(tert-butoxycarbonyl)guanidino-8-chloro-2,3,4,5-
tetrahydro-1-benzoxepine (23). A solution of 8-chloro-5-(2′,2′-
dichloromethylcarbonylamino)-2,3,4,5-tetrahydro-1-benzoxepine (21)
(0.067 g, 0.219 mmol) was dissolved in methanol (1 mL) and added
to 6 M hydrochloric acid (10 mL). The reaction mixture was heated at
100 °C for 144 h. The methanol was removed in vacuo, and the
aqueous layer was extracted with diethyl ether (3 × 10 mL). The
remaining aqueous layer was basiﬁed by adding sodium carbonate
solution and extracted with diethyl ether (3 × 10 mL). The combined
organic extracts were concentrated to aﬀord 5-amino-8-chloro-2,3,4,5-
tetrahydro-1-benzoxepine (0.033 g) as a white solid. This was used in
the next step without further puriﬁcation. Diisopropylethylamine
(0.237 mL, 1.40 mmol) and N,N′-bis(tert-butoxycarbonyl-1H-
pyrazole-1-carboxamidine (22) (0.079 g, 0.260 mmol) were added
to a solution of 5-amino-8-chloro-2,3,4,5-tetrahydro-1-benzoxepine
(0.033 g, 0.170 mmol) in methanol (10 mL) and stirred for 48 h at
room temperature. The methanol was removed in vacuo. The resulting
residue was dissolved in diethyl ether (10 mL) and acidiﬁed by 0.2 M
hydrochloric acid (1 mL). The solution was washed with water (10
mL), brine (10 mL), dried (MgSO4), and concentrated in vacuo.
Puriﬁcation by column chromatography (elution with 7% diethyl ether
in petroleum ether) gave 5-N,N′-bis(tert-butoxycarbonyl)guanidino-8-
chloro-2,3,4,5-tetrahydro-1-benzoxpine (23) (0.071 g, 75%) as a white
solid. Mp 169−171 °C (decomposition); IR (neat) 3321, 2981, 1722,
1637, 1612, 1560, 1479, 1412, 1324, 1227, 1154, 1124, 1057, 909, 732
cm−1; 1H NMR (400 MHz, CDCl3) δ 1.48 (s, 9H), 1.50 (s, 9H),
1.72−1.80 (m, 1H), 1.85−1.93 (m, 1H), 2.15−2.27 (m, 2H), 3.80
(ddd, J = 12.0, 10.1, 2.1 Hz, 1H), 4.31 (dt, J = 12.0, 4.2 Hz, 1H), 5.50
(ddd, J = 9.0, 6.6, 2.0 Hz, 1H), 7.02 (dd, J = 8.1, 2.1 Hz, 1H), 7.05 (d, J
= 2.1 Hz, 1H), 7.24 (d, J = 8.1 Hz, 1H), 9.01 (d, J = 9.0 Hz, 1H), 11.46
(s, 1H); 13C NMR (101 MHz, CDCl3) δ 26.9 (CH2), 28.1 (3 × CH3),
28.3 (3 × CH3), 30.4 (CH2), 52.5 (CH), 73.9 (CH2), 79.2 (C), 83.1
(C), 122.7 (CH), 124.1 (CH), 130.5 (CH), 133.1 (C), 133.8 (C),
153.0 (C), 155.1 (C), 160.3 (C), 163.7 (C); MS (EI) m/z 439 (M+,
10), 383 (8), 327 (63), 266 (35), 196 (11), 181 (24), 82 (44), 59
(100); HRMS (EI) calcd for C21H30
35ClN3O5 (M
+), 439.1874, found
439.1873.
8-Chloro-5-guanidino-2,3,4,5-tetrahydro-1-benzoxepine tri-
ﬂuoroacetic acid (4). A solution of 5-N,N′-bis(tert-butoxycarbonyl)-
guanidino-8-chloro-2,3,4,5-tetrahydro-1-benzoxpine (23) (0.012 g,
0.027 mmol) in dichloromethane (0.450 mL) and triﬂuoroacetic
acid (0.011 mL, 0.140 mmol) was stirred at 45 °C for 48 h. The
reaction mixture was concentrated in vacuo to aﬀord 8-chloro-5-
guanidino-2,3,4,5-tetrahydro-1-benzoxepine triﬂuoroacetic acid (4)
(0.007 g, 100%) as a white solid. Mp 229−231 °C (decomposition);
IR (neat) 3364, 3160, 2925, 1679, 1613, 1481, 1201, 1187, 1144, 972,
843, 801, 724 cm−1; 1H NMR (400 MHz, CD3OD) δ 1.96−2.16 (m,
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4H), 4.00 (ddd, J = 9.6, 5.2, 2.4 Hz, 1H), 4.07 (ddd, J = 9.6, 5.6, 2.8
Hz, 1H), 4.84 (t, J = 4.0 Hz, 1H), 7.08 (d, J = 2.1 Hz, 1H), 7.12 (dd, J
= 8.2, 2.1 Hz, 1H), 7.21 (d, J = 8.2 Hz, 1H); 13C NMR (101 MHz,
CD3OD) δ 27.2 (CH2), 31.2 (CH2), 53.7 (CH), 73.1 (CH2), 122.4
(CH), 123.8 (CH), 128.1 (CH), 132.5 (C), 133.9 (C), 156.5 (C),
159.7 (C); MS (ESI) m/z 240 (MH+, 25); HRMS (ESI) calcd for
C11H15
35ClN3O (MH
+), 240.0898, found 240.0902.
(3R*,4S*,5S*)-3,4-Dihydroxy-6-methoxy-5-(2′,2′,2′-trichlor-
omethylcarbonylamino)-2,3,4,5-tetrahydro-1-benzoxepine
(24). Tetramethylethylenediamine (0.019 mL, 0.13 mmol) was added
to a solution of 6-methoxy-5-(2′,2′,2′-trichloromethylcarbonylamino)-
2,5-dihydro-1-benzoxepine (11b) (0.039 g, 0.12 mmol) in dichloro-
methane (2 mL) and cooled to −78 °C. After 0.2 h, a solution of
osmium tetroxide (0.032 g, 0.13 mmol) in dichloromethane (1 mL)
was added dropwise. The solution was stirred at −78 °C for 1 h,
allowed to return to room temperature over 2 h, then concentrated in
vacuo. The residue was taken up in a solution of methanol (4 mL) and
12 M hydrochloric acid (0.5 mL) and stirred at room temperature for
2 h. The reaction mixture was concentrated in vacuo. The resulting
residue was puriﬁed by column chromatography (elution with 50%
ethyl acetate in petroleum ether) to yield (3R*,4S*,5S*)-3,4-
dihydroxy-6-methoxy-5-(2′,2′,2′-trichloromethylcarbonylamino)-
2,3,4,5-tetrahydro-1-benzoxepine (24) (0.032 g, 74%) as a colorless
oil. IR (neat) 3464, 3417, 2928, 1711, 1505, 1473, 1249, 1086, 820
cm−1; 1H NMR (500 MHz, CDCl3) δ 2.72 (s, 1H), 2.95 (s, 1H), 3.68
(t, J = 12.4 Hz, 1H), 3.85 (s, 3H), 4.16−4.26 (m, 2H), 4.50 (dd, J =
6.6, 4.0 Hz, 1H), 6.01 (dd, J = 8.4, 6.6 Hz, 1H), 6.72 (d, J = 8.2 Hz,
1H), 6.75 (d, J = 8.2 Hz, 1H), 7.27 (t, J = 8.2 Hz, 1H), 7.31 (d, J = 8.4
Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 47.5 (CH), 56.4 (CH3),
68.4 (CH), 69.0 (CH), 71.2 (CH2), 92.5 (C), 107.9 (CH), 114.4
(CH), 117.3 (C), 130.8 (CH), 158.9 (C), 160.2 (C), 161.7 (C); MS
(ESI) m/z 392 (MNa+, 100); HRMS (ESI) calcd for
C13H14
35Cl3NNaO5 (MNa
+), 391.9830, found 391.9818.
(3S*,4S*,5S*)-7-Chloro-3,4-dihydroxy-5-(2′,2′,2′-trichloro-
methylcarbonylamino)-2,3,4,5-tetrahydro-1-benzoxepine (26).
3-Chloroperbenzoic acid (0.10 g, 0.59 mmol) was added to a stirred
solution of 7-chloro-5-(2′,2′,2′-trichloromethylcarbonylamino)-2,5-
dihydro-1-benzoxepine (11g) (0.050 g, 0.15 mmol) in dichloro-
methane (3 mL) at 0 °C. The reaction mixture was stirred and allowed
to warm from 0 °C to room temperature over 18 h, then cooled to 0
°C before 3-chloroperbenzoic acid (0.10 g, 0.59 mmol) was added.
The reaction mixture was stirred for a further 24 h, quenched by the
addition of a saturated solution of sodium sulﬁte (5 mL), and extracted
with dichloromethane (2 × 5 mL). The combined organic layers were
washed with a saturated solution of sodium hydrogen carbonate (3 ×
10 mL), water (10 mL), and brine (10 mL), then dried (MgSO4),
ﬁltered, and concentrated in vacuo. This gave a crude mixture
containing (3R*,4S*,5S*)-7-chloro-3,4-epoxy-5-(2′,2′,2′-trichlorome-
thylcarbonylamino)-2,3,4,5-tetrahydro-1-benzoxepine (25) which was
used in the next step without further puriﬁcation. 1.0 M Sulfuric acid
(2 mL) was added to a solution of the crude mixture containing
(3R*,4S*,5S*)-7-chloro-3,4-epoxy-5-(2′,2′,2′-trichloromethylcarbony-
lamino)-2,3,4,5-tetrahydro-1-benzoxepine (25) in 1,4-dioxane (2 mL)
and stirred at room temperature for 48 h. The reaction was quenched
by addition of a saturated solution of sodium hydrogen carbonate (3
mL) and extracted with diethyl ether (2 × 10 mL). The organic layer
was washed with water (10 mL), brine (10 mL), then dried (MgSO4),
ﬁltered, and concentrated in vacuo. Puriﬁcation by column
chromatography (elution with 50% ethyl acetate in petroleum ether)
gave (3S*,4S*,5S*)-7-chloro-3,4-dihydroxy-5-(2′,2′,2′-trichlorome-
thylcarbonylamino)-2,3,4,5-tetrahydro-1-benzoxepine (26) (0.031 g,
57%) as a white foam. IR (neat) 3404, 2927, 1696, 1507, 1482, 1228,
1081, 823 cm−1; 1H NMR (400 MHz, CDCl3) δ 2.70 (d, J = 3.7 Hz,
1H), 3.33 (d, J = 5.3 Hz, 1H), 3.76 (dd, J = 12.3, 8.4 Hz, 1H), 3.85−
3.92 (m, 1H), 4.07 (ddd, J = 11.7, 8.4, 3.6 Hz, 1H), 4.35 (dd, J = 12.3,
3.6 Hz, 1H), 5.33 (dd, J = 8.0, 1.5 Hz, 1H), 7.02−7.10 (m, 1H), 7.27−
7.31 (m, 2H), 7.35 (d, J = 8.0 Hz, 1H); 13C NMR (126 MHz, CDCl3)
δ 57.1 (CH), 71.1 (CH), 73.9 (CH2), 75.8 (CH), 92.3 (C), 123.9
(CH), 129.7 (CH), 130.5 (C), 130.6 (C), 130.7 (CH), 157.3 (C),
163.2 (C); MS (ESI) m/z 396 (MNa+, 100); HRMS (ESI) calcd for
C12H11
35Cl4NNaO4 (MNa
+), 395.9334, found 395.9321.
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